Editing Amgen

{{Short description|American multinational biopharmaceutical company}}
{{third-party|date=August 2020}}

{{Infobox company
| name = Amgen Inc.
| former_names = Applied Molecular Genetics (1980–1983)
| logo = Amgen.svg
| logo_size = 250px
| image = Amgenheadquarters.jpg
| image_size = 250px
| image_caption = Headquarters in Thousand Oaks, California
| type = [[Public company|Public]]
| ISIN = {{ISIN|sl=n|pl=y|US0311621009}}
| traded_as = {{ubl|{{NASDAQ|AMGN}}|[[Nasdaq-100]] component|[[DJIA]] component|[[S&P 100]] component|[[S&P 500]] component}}
| key_people = [[Robert A. Bradway]] ([[chairman]], [[President (corporate title)|president]] & [[Chief executive officer|CEO]])
| industry = [[Biotechnology]]
| products = {{hlist|[[Aimovig]]|[[Aranesp]]|[[Blincyto]]|[[Epogen]]|[[Anakinra|Kineret]]|[[Enbrel]]|[[Kyprolis]]|[[Neulasta]]|[[Neupogen]]|[[Nplate]]|[[Parsabiv]]|[[Prolia]]|[[Repatha]]|[[Sensipar]]/[[Mimpara]]|[[Vectibix]]|[[Xgeva]]}}
| revenue = {{increase}} {{US$|33.4 billion|link=yes}} (2024)
| operating_income = {{decrease}} {{US$|7.26 billion}} (2024)
| net_income = {{decrease}} {{US$|4.09 billion}} (2024)
| assets = {{decrease}} {{US$|91.8 billion}} (2024)
| equity = {{decrease}} {{US$|5.88 billion}} (2024)
| num_employees = 28,000 (2024)
| foundation = {{start date and age|1980|4|8}}
| location = {{nowrap|[[Thousand Oaks, California]], U.S.}}
| website = {{URL|https://amgen.com/}}
| footnotes = <ref name="quickfacts2020">{{cite web|title=About Amgen Fact Sheet|url=https://wwwext.amgen.com/~/media/amgen/full/www-amgen-com/downloads/fact-sheets/fact_sheet_amgen.ashx|website=amgen.com|access-date=9 March 2020}}</ref><ref>{{Cite web |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/318154/000031815425000010/amgn-20241231.htm |title=2024 Annual Report (Form 10-K) |date=February 14, 2025 |publisher=[[U.S. Securities and Exchange Commission]]}}</ref>
}}

'''Amgen Inc.''' (formerly '''Applied Molecular Genetics Inc.''') is an American multinational [[biopharmaceutical]] [[Corporation|company]] headquartered in [[Thousand Oaks, California]].<ref>[http://www.amgenhistory.com/ Amgen History official site] page accessed January 2, 2016</ref><ref>Ronald Vogel. Pharmaceutical Economics and Public Policy. CRC Press, 2007. {{ISBN|9781439801345}}. [https://books.google.com/books?id=ejNC3HJmjhwC&pg=PA208 P. 208]</ref> As one of the world's largest independent [[biotechnology]] companies, Amgen has approximately 24,000 staff in total as of 2022.<ref name="Talhelm">{{cite news |last1=Talhelm |first1=Matt |date=7 March 2022 |title=Amgen to offer workers an average salary of $119,510 at new facility |work=WRAL TechWire |url=https://wraltechwire.com/2022/03/07/amgen-to-officially-break-ground-on-550-million-facility-in-holly-springs/ |access-date=20 September 2022}}</ref>

The name "AMGen" is a [[portmanteau]] of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its [[initial public offering]]). The company is listed on the Nasdaq Global Select Market under the ticker symbol "AMGN", as well as a component of the [[Nasdaq-100]], the [[Dow Jones Industrial Average]], and the [[S&P 100]] and [[S&P 500|500]] indices.

== History ==
[[Image:AMGenelogo.jpg|thumb|right|AMGen corporate logo, 1983]]
[[File:Macri Amgen.jpg|thumb|Argentine president [[Mauricio Macri]] meets with heads of Amgen, in 2018.]]
Amgen was established in Thousand Oaks in 1980, as Applied Molecular Genetics.<ref>Bidwell, Carol A. (1989). ''The Conejo Valley: Old and New Frontiers''. Windsor Publications. p. 128. {{ISBN|978-0897812993}}.</ref><ref name="Baker, Pam 2002 Page 37">Baker, Pam (2002). ''Thousand Oaks Westlake Village: A Contemporary Portrait''. Community Communications, Inc., p. 37. {{ISBN|978-1581920611}}.</ref> Amgen was backed by a small group of venture capitalists, and its early focus was on [[recombinant DNA]] technology and recombinant human [[insulin]].<ref name="Walsh">{{cite web |last1=Walsh |first1=Robin |date=27 October 2010 |title=A history of: Amgen |url=https://pharmaphorum.com/views-and-analysis/a_history_of_amgen/ |access-date=10 August 2022 |website=pharmaphorum.com}}</ref>

Its initial scientific advisory board consisted of [[Norman Davidson (biologist)|Norman Davidson]], [[Leroy Hood]], [[Arnold Berk]], [[John Carbon]], [[Robert Schimke]], [[Arno Motulsky]], [[Marvin H. Caruthers]], and Dave Gibson.<ref>{{cite web |title=Amgen—A biotechnology success story {{!}} From drug development to the mass market |url=https://www.marsdd.com/mars-library/amgen-a-biotechnology-success-story-from-drug-development-to-the-mass-market/ |url-status=dead |archive-url=https://web.archive.org/web/20141024024858/https://www.marsdd.com/mars-library/amgen-a-biotechnology-success-story-from-drug-development-to-the-mass-market/ |archive-date=2014-10-24 |access-date=2016-09-12}}</ref> In October 1980, Amgen named [[George Rathmann]] its first president and chief executive officer.<ref name="Walsh" />

On June 17, 1983, Amgen went public, selling two million [[common shares]] and raising nearly $40 million.<ref>{{cite web |date=1 September 1983 |title=Small Company Initial Public Offerings: June 1983 |url=https://www.inc.com/magazine/19830901/2878.html |access-date=10 August 2022 |website=Inc.com |language=en}}</ref><ref>{{cite web |last1=Ward |first1=Nicholas |date=21 April 2019 |title=Amgen: This Beaten Down Blue Chip Is Priced To Own |url=https://www.thestreet.com/investing/stocks/amgen-this-beaten-down-blue-chip-is-priced-to-own-14930489 |access-date=10 August 2022 |website=TheStreet |language=en-us}}</ref><ref>{{cite web |last1=Timmerman |first1=Luke |date=13 May 2002 |title=Shrewd science: Biotech giant Amgen's success reflects its savvy corporate style |url=https://archive.seattletimes.com/archive/?date=20020513&slug=amgen130 |access-date=10 August 2022 |website=The Seattle Times}}</ref> That same year, after more than two years of work, an Amgen research team led by [[Fu-Kuen Lin]] had a breakthrough in finding and cloning the [[erythropoietin]] gene, a protein created in the kidney that stimulates [[red blood cell]] production. Lin's team created what would become Epogen ([[epoetin alfa]]).<ref>{{cite web |last1=Bate |first1=James |date=2 June 1989 |title=Biotech Detective Scores Coup : Amgen scientist spent years searching for the key to producing EPO. |url=https://www.latimes.com/archives/la-xpm-1989-06-02-fi-1020-story.html |access-date=10 August 2022 |website=Los Angeles Times}}</ref><ref name="Kim">{{cite book |last1=Kim |first1=Rachel |url=https://books.google.com/books?id=Qah8DwAAQBAJ |title=Economics and management in the biopharmaceutical industry in the USA : evolution and strategic change |date=2019 |publisher=Routledge |isbn=9781351012690 |location=London |pages=2002–2003 |access-date=10 August 2022}}</ref>

In 1985, Amgen researcher Larry Souza and his team cloned [[granulocyte colony-stimulating factor]] (G-CSF), leading to the development of Neupogen ([[filgrastim]]).<ref name="Kim" /><ref>{{cite news |last1=Murphy |first1=Barbara |date=20 May 1997 |title=Souza to Run Research at Biotech King Amgen |url=https://www.latimes.com/archives/la-xpm-1997-05-20-fi-60727-story.html |access-date=10 August 2022 |work=Los Angeles Times}}</ref><ref>{{cite journal |last1=Bendall |first1=Linda J. |last2=Bradstock |first2=Kenneth F. |date=August 2014 |title=G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent |journal=Cytokine & Growth Factor Reviews |volume=25 |issue=4 |pages=355–367 |doi=10.1016/j.cytogfr.2014.07.011 |pmid=25131807 |doi-access=free}}</ref>

In October 1988, [[Gordon Binder]] was named CEO, succeeding George Rathmann.<ref>{{cite news |date=17 October 1995 |title=Gordon M. Binder, chief executive of Amgen... |url=https://www.latimes.com/archives/la-xpm-1995-10-17-fi-58041-story.html |access-date=10 August 2022 |work=Los Angeles Times}}</ref> The following year, in 1989, Amgen received approval for the first recombinant human erythropoetin product, Epogen ([[epoetin alfa]]).<ref name="auto">{{cite web |title=Drugs@FDA: FDA Approved Drug Products |url=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=103795&DrugName=ENBREL&ActiveIngred=ETANERCEPT&SponsorApplicant=IMMUNEX&ProductMktStatus=1&goto=Search.DrugDetails}}{{dead link|date=May 2025|bot=medic}}{{cbignore|bot=medic}}</ref><ref>{{cite news |date=19 July 2012 |title=Amgen and its erythropoietin drugs |url=https://www.washingtonpost.com/wp-srv/business/amgen-anemia-drugs/index.html |access-date=20 September 2022 |newspaper=The Washington Post |language=en}}</ref>

In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy.<ref>{{cite web |title=Drugs@FDA: FDA Approved Drug Products |url=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=103353&DrugName=NEUPOGEN&ActiveIngred=FILGRASTIM&SponsorApplicant=AMGEN&ProductMktStatus=1&goto=Search.DrugDetails}}{{dead link|date=May 2025|bot=medic}}{{cbignore|bot=medic}}</ref><ref>{{Cite news |last1=Pollack |first1=Andrew |last2=Times |first2=Special To the New York |date=1991-02-22 |title=An F.D.A. Approval for Amgen |url=https://www.nytimes.com/1991/02/22/business/an-fda-approval-for-amgen.html |access-date=2024-05-29 |work=The New York Times |language=en-US |issn=0362-4331}}</ref>

Amgen opened a new manufacturing facility in [[Puerto Rico]], in March 1993, which later became the company's flagship manufacturing site.<ref>{{cite news |last1=Spencer |first1=Dina |date=26 Sep 2019 |title=5 Top Pharma Manufacturers in Puerto Rico |url=https://pharmaboardroom.com/articles/5-top-pharma-manufacturers-in-puerto-rico/ |access-date=10 August 2022 |work=PharmaBoardroom}}</ref><ref>{{Cite web |last=Apodaca |first=Patrice |date=1993-08-17 |title=Amgen to Open Puerto Rico Plant Despite Tax Credit Cut : Biotechnology: Analysts say the benefit reduction does not alter expectations of strong long-term growth for the Thousand Oaks giant. |url=https://www.latimes.com/archives/la-xpm-1993-08-17-fi-24667-story.html |access-date=2024-05-29 |website=Los Angeles Times |language=en-US}}</ref>

In 1994, Amgen became the fifth company to receive the [[United States Department of Commerce|U.S. Department of Commerce]]'s [[National Medal of Technology and Innovation]], in recognition of its work developing medicines to improve quality of life for kidney and cancer patients.<ref>{{cite news |last1=Nathans |first1=Aaron |date=16 September 1994 |title=Amgen, Phone Entrepreneur Win Medal of Technology |url=https://www.latimes.com/archives/la-xpm-1994-09-16-fi-39443-story.html |access-date=10 August 2022 |work=Los Angeles Times}}</ref> Also around this time, Amgen researcher Steve Elliott and his team added more sugar molecules to erythropoietin, causing it to remain in the body longer. This led to the development of Aranesp ([[darbepoetin alfa]]).<ref>{{cite news |date=3 Sep 2001 |title=A Biotech Wonder Grows Up |url=https://www.forbes.com/forbes/2001/0903/118.html?sh=7bd567cd5244 |access-date=10 August 2022 |work=Forbes |language=en}}</ref>

=== 2000-2014 ===
Binder was succeeded as CEO by [[Kevin W. Sharer]] in 2000.<ref>{{Cite web |title=Amgen names new CEO - May 11, 2000 |url=https://money.cnn.com/2000/05/11/news/amgen/index.htm |access-date=2024-11-04 |website=money.cnn.com}}</ref> Robert A. Bradway became Amgen's president and chief executive officer in May 2012, following Sharer's retirement.<ref name="Amgen-May-2012-8-K">{{cite web|url=http://edgar.secdatabase.com/1218/119312512245437/filing-main.htm |title=Amgen, Form 8-K, Current Report, Filing Date May 24, 2012 |publisher=secdatabase.com |access-date =Jan 8, 2013}}</ref>

In March 2011, Amgen acquired a manufacturing facility near Dublin, Ireland, in March.<ref>{{cite news |date=11 March 2011 |title=Amgen to buy Pfizer plant |url=https://www.irishtimes.com/business/health-pharma/amgen-to-buy-pfizer-plant-1.873076 |access-date=10 August 2022 |newspaper=The Irish Times |language=en}}</ref>

Amgen also opened an affiliate in China in 2013.<ref>{{cite news |last1=Becker |first1=Zoey |date=27 June 2022 |title=Amgen partners with Fosun to bring Otezla, Parsabiv to patients in China |url=https://www.fiercepharma.com/pharma/amgen-partners-fosun-pharma-bring-psoriasis-chronic-kidney-disease-medicines-country |work=Fierce Pharma |language=en}}</ref><ref>{{cite news |last1=Philippidis |first1=Alex |date=1 November 2019 |title=Amgen Expands China Presence, Cancer R&D with $2.7B BeiGene Collaboration |url=https://www.genengnews.com/news/amgen-expands-china-presence-cancer-rd-with-2-7b-beigene-collaboration/ |access-date=11 August 2022 |work=GEN - Genetic Engineering and Biotechnology News}}</ref>

In November 2014 the company announced it was halting all trials of [[rilotumumab]] in advanced [[gastric cancer]] patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without.<ref>{{cite web |date=24 November 2014 |title=GEN - News Highlights:Amgen Halts Rilotumumab Trials in Advanced Gastric Cancer |url=http://www.genengnews.com/gen-news-highlights/amgen-halts-rilotumumab-trials-in-advanced-gastric-cancer/81250637/ |work=GEN}}</ref> Later in the same week, the company in conjunction with [[AstraZeneca]] reported positive results for [[brodalumab]] in a Phase III trial comparing the compound with [[ustekinumab]] and a [[placebo]] in treating [[psoriasis]].<ref>{{cite web |title=GEN - News Highlights:Brodalumab's No Turkey in Phase III: Amgen and AstraZeneca |url=http://www.genengnews.com/gen-news-highlights/brodalumab-s-no-turkey-in-phase-iii-amgen-and-astrazeneca/81250645/ |work=GEN}}</ref> In the same month, construction was completed on Amgen's next-generation biomanufacturing facility in Singapore.<ref>{{cite news |last1=Brennan |first1=Zachary |date=21 November 2014 |title=Amgen launches $200m biomanufacturing facility in Singapore |url=https://www.biopharma-reporter.com/Article/2014/11/21/Amgen-launches-200m-biomanufacturing-facility-in-Singapore |access-date=11 August 2022 |work=BioPharma-Reporter}}</ref> Blincyto ([[blinatumomab]]) was approved by the FDA in December of that year.<ref>{{cite journal |last1=Przepiorka |first1=Donna |last2=Ko |first2=Chia-Wen |last3=Deisseroth |first3=Albert |last4=Yancey |first4=Carolyn L. |last5=Candau-Chacon |first5=Reyes |last6=Chiu |first6=Haw-Jyh |last7=Gehrke |first7=Brenda J. |last8=Gomez-Broughton |first8=Candace |last9=Kane |first9=Robert C. |last10=Kirshner |first10=Susan |last11=Mehrotra |first11=Nitin |last12=Ricks |first12=Tiffany K. |last13=Schmiel |first13=Deborah |last14=Song |first14=Pengfei |last15=Zhao |first15=Ping |date=15 September 2015 |title=FDA Approval: Blinatumomab |url=https://pubmed.ncbi.nlm.nih.gov/26374073/ |journal=Clinical Cancer Research |volume=21 |issue=18 |pages=4035–4039 |doi=10.1158/1078-0432.CCR-15-0612 |issn=1557-3265 |pmid=26374073 |s2cid=207687724 |access-date=11 August 2022 |last16=Zhou |first16=Qing |last17=Farrell |first17=Ann T. |last18=Pazdur |first18=Richard}}</ref><ref>{{cite news |date=15 December 2014 |title=FDA Approves Blinatumomab to Treat Rare Form of Acute Lymphoblastic Leukemia |url=https://ascopost.com/issues/december-15-2014/fda-approves-blinatumomab-to-treat-rare-form-of-acute-lymphoblastic-leukemia/ |access-date=11 August 2022 |work=The ASCO Post |language=en}}</ref>

Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000<ref>{{cite news |last1=Biasotti |first1=Tony |date=9 April 2022 |title=In Thousand Oaks, biotech execs discuss industry's 'rising tide,' lament area's lack of housing |url=https://www.pacbiztimes.com/2022/04/08/in-thousand-oaks-biotech-execs-discuss-industrys-rising-tide-lament-areas-lack-of-housing/ |access-date=19 September 2022 |work=Pacific Coast Business Times}}</ref> (8.5% of total city employment)<ref>{{cite news |date=30 June 2021 |title=Annual Comprehensive Financial Report |url=https://www.toaks.org/home/showpublisheddocument?id=39338 |access-date=19 September 2022 |work=City of Thousand Oaks, California |page=156}}</ref> and included hundreds of scientists, making Amgen the largest employer in [[Ventura County, California|Ventura County]].<ref name="Baker, Pam 2002 Page 37" /><ref>{{cite web |date=16 February 2018 |title=Biotech giant Amgen has big plans for new plant |url=https://www.mpacorn.com/articles/biotech-giant-amgen-has-big-plans-for-new-plant/ |website=Moorpark Acorn}}</ref>

==Timeline==
{{prose|date=October 2024}}
*1984: In June, Amgen and Kirin formed a joint venture giving Kirin the rights to Epogen in Japan.<ref>{{cite news |title=Kirin and Amgen Hormone Venture |url=https://www.nytimes.com/1984/06/15/business/kirin-and-amgen-hormone-venture.html |work=The New York Times |date=15 June 1984 |agency=Reuters |access-date=10 August 2022}}</ref><ref>{{Cite web |date=31 October 2017 |title=Japan's Kirin cashes out of Amgen drug joint venture |url=https://www.reuters.com/article/idUSKBN1D00YO/ |access-date=22 November 2024 |website=Reuters}}</ref>
*2002:  In July, Amgen acquired Immunex, the developer of Enbrel (etanercept).<ref>{{cite news |last1=Pollack |first1=Andrew |title=Amgen Reports Its Takeover Of Immunex |url=https://www.nytimes.com/2002/07/17/business/amgen-reports-its-takeover-of-immunex.html |access-date=10 August 2022 |work=The New York Times |date=17 July 2002}}</ref>
*2004:  Also, Amgen acquired Tularik, another biotechnology company, expanding the company's research and development pipeline.<ref>{{cite news |last1=Gellene |first1=Denise |title=Amgen to Buy Rival Tularik |url=https://www.latimes.com/archives/la-xpm-2004-mar-30-fi-amgen30-story.html |access-date=10 August 2022 |work=Los Angeles Times |date=30 March 2004}}</ref><ref>{{cite web |title=Amgen buys remaining 79% of Tularik for $1.3B to boost R&D pipeline |url=https://www.thepharmaletter.com/article/amgen-buys-remaining-79-of-tularik-for-1-3b-to-boost-r-d-pipeline |website=The Pharma Letter |date=4 April 2004 |access-date=10 August 2022}}</ref>
*2006: In April, Amgen acquired Abgenix, the developer of Vectibix ([[panitumumab]]), a treatment developed for certain patients with metastatic [[colorectal cancer]].<ref>{{cite news |last1=Pollack |first1=Andrew |title=Amgen to Buy Abgenix, Getting Complete Control of New Colon Cancer Drug |url=https://www.nytimes.com/2005/12/15/business/amgen-to-buy-abgenix-getting-complete-control-of-new-colon-cancer.html |work=The New York Times |date=15 December 2005 |access-date=10 August 2022}}</ref><ref>{{Cite web |title=Amgen Completes Acquisition of Abgenix |url=https://www.technologynetworks.com/genomics/news/amgen-completes-acquisition-of-abgenix-186294 |access-date=2025-01-27 |website=Genomics Research from Technology Networks |language=en}}</ref>
* 2010: On June 6, 2010, Amgen received [[Food and Drug Administration|FDA]] approval for Prolia, a protein drug for the treatment of post-menopausal osteoporosis.<ref>{{cite web |url=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125320&DrugName=PROLIA&ActiveIngred=DENOSUMAB&SponsorApplicant=AMGEN&ProductMktStatus=1&goto=Search.Label_ApprovalHistory |title=Drugs@FDA: FDA Approved Drug Products }}{{dead link|date=May 2025|bot=medic}}{{cbignore|bot=medic}}</ref> In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%.<ref>{{cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s0000lbl.pdf |title=www.accessdata.fda.gov }}</ref> In November 2010 the [[Food and Drug Administration|FDA]] approved Xgeva for the prevention of complications of bone metastases in patients with solid tumors.<ref>{{cite web |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm234346.htm |archive-url=https://web.archive.org/web/20101121233928/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm234346.htm |url-status=dead |archive-date=November 21, 2010 |title=FDA approves Xgeva to help prevent cancer-related bone injury |website=[[Food and Drug Administration]] }}</ref> The clinical trials primarily enrolled patients with breast or prostate cancer.
*2011: In May, Amgen acquired BioVex,<ref>{{cite news |last1=Timmerman |first1=Luke |title=Xconomy: Amgen to Acquire BioVex for Up To $1B, to Obtain Cancer-Killing Virus Therapy |url=https://xconomy.com/boston/2011/01/24/amgen-to-acquire-biovex-for-up-to-1b-to-obtain-cancer-killing-virus-therapy/ |work=Xconomy |date=24 January 2011 |language=en |access-date=10 August 2022}}</ref><ref>{{Cite web |last=Brown |first=Steven E.F. |date=24 January 2011 |title=Amgen buying BioVex for $425 million |url=https://www.bizjournals.com/sanfrancisco/news/2011/01/24/amgen-buying-biovex-for-425-million.html |access-date=2024-10-10 |website=San Francisco Business Times}}</ref> developer of Imlygic ([[talimogene laherparepvec]]).<ref>{{cite news |last1=Dangi-Garimella |first1=Surabhi |title=Cost Questions Will Follow the Approval of Amgen's Oncolytic Viral Treatment, Imlygic |url=https://www.ajmc.com/view/cost-questions-will-follow-the-approval-of-amgens-oncolytic-viral-treatment-imlygic |access-date=10 August 2022 |work=AJMC |date=28 October 2015 |language=en}}</ref> In December, Amgen and [[Watson Pharmaceuticals]] announced a collaboration to develop and commercialize several [[biosimilar]] medicines worldwide.<ref>{{cite news |last1=Pollack |first1=Andrew |title=Amgen Plans to Team Up With Watson on Generics |url=https://www.nytimes.com/2011/12/20/health/research/amgen-and-watson-to-work-together-on-generic-drugs.html?_r=1 |work=The New York Times |date=20 December 2011 |access-date=10 August 2022}}</ref><ref>{{Cite web |date=19 December 2011 |title=Amgen and Watson strike $400M cancer biosimilars pact |url=https://www.fiercebiotech.com/r-d/updated-amgen-and-watson-strike-400m-cancer-biosimilars-pact |access-date=10 October 2024 |website=Fierce Biotech}}</ref>
*2012: Amgen acquired Micromet, a company focused on [[Bi-specific T-cell engager|BiTE]] technology.<ref>{{cite news |date=26 January 2012 |title=Amgen to buy Micromet for $1.2 billion |url=https://www.reuters.com/article/us-micromet-amgen/amgen-to-buy-micromet-for-1-2-billion-idUSTRE80P0X920120126 |access-date=10 August 2022 |work=Reuters |language=en}}</ref><ref>{{Cite web |date=31 January 2012 |title=Amgen Agrees to Pay 1.16 Billion for Micromet and Its Oncology Drugs |url=https://news.bloomberglaw.com/pharma-and-life-sciences/amgen-agrees-to-pay-116-billion-for-micromet-and-its-oncology-drugs |access-date=10 October 2024 |website=Bloomberg Law}}</ref>
* 2013: Lawmakers inserted text into the fiscal cliff bill that would allow the drugmaker to sell a class of drugs that includes Sensipar without government controls for an additional two years. The New York Times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated $500 million<ref>{{cite news|last=Lipton|first=Eric|title=Fiscal Footnote: Big Senate Gift to Drug Maker|url=https://www.nytimes.com/2013/01/20/us/medicare-pricing-delay-is-political-win-for-amgen-drug-maker.html?pagewanted=all|work=[[The New York Times]]|access-date=2 February 2013|date=19 January 2013}}</ref> but other assessments concluded that the change would protect seniors in rural areas and reduce overall Medicare spending.<ref>{{cite news |url=https://www.huffingtonpost.com/jon-entine/after-congressional-budge_b_2759676.html |title=Jon Entine: New York Times Mum After Congressional Budget Office Rebukes Bungled Amgen/Medicare Investigation |work= Huffington Post|date=26 February 2013}}</ref><ref>{{cite web|url=http://www.nephrologynews.com/articles/109331-cbo-analysis-shows-keeping-oral-drugs-out-of-esrd-bundle-could-save-money |archive-url=https://web.archive.org/web/20130605171126/http://www.nephrologynews.com/articles/109331-cbo-analysis-shows-keeping-oral-drugs-out-of-esrd-bundle-could-save-money |url-status=dead |archive-date=2013-06-05 |title=CBO analysis shows keeping oral drugs out of ESRD bundle could save money &#124; Nephrology News & Issues }}</ref>  In May, Kevin Sharer retired, and Robert Bradway, formerly Amgen's president and chief operating officer, became CEO.<ref>{{cite news |title=Amgen appoints CEO Robert Bradway to chair of board |url=https://www.pmlive.com/pharma_appointments/amgen_appoints_ceo_robert_bradway_to_chair_of_board_456016 |access-date=10 August 2022 |work=PMLive |date=17 December 2012 |language=en}}</ref> In June, Amgen acquired Turkish company Mustafa Nevzat Pharmaceuticals, expanding Amgen's presence in Turkey and nearby areas.<ref>{{cite news |last1=Writer |first1=GEN Staff |title=Amgen Ponies Up $700M for Turkey's Mustafa Nevzat |url=https://www.genengnews.com/news/amgen-ponies-up-700m-for-turkeys-mustafa-nevzat/ |access-date=10 August 2022 |work=GEN - Genetic Engineering and Biotechnology News |date=25 April 2012}}</ref> In July, Amgen acquired KAI Pharmaceuticals, developer of Parsabiv ([[etelcalcetide]]).<ref>{{cite news |title=Amgen to Pick Up Peptide Drug Firm KAI Pharmaceuticals for $315M |url=https://www.genengnews.com/news/amgen-to-pick-up-peptide-drug-firm-kai-pharmaceuticals-for-315m/ |work=GEN - Genetic Engineering and Biotechnology News |date=10 April 2012}}</ref><ref>{{cite news |last1=Taylor |first1=Phil |title=Amgen's chronic kidney disease drug Parsabiv cleared in US |url=https://www.pmlive.com/pharma_news/amgens_chronic_kidney_disease_drug_parsabiv_cleared_in_us_1185993 |access-date=11 August 2022 |work=PMLive |date=8 February 2017 |language=en}}</ref> Amgen acquired Iceland-based [[DeCODE genetics|deCODE Genetics]] in December.<ref>{{cite news |title=Amgen Buys deCODE Genetics for $415M |url=https://www.genengnews.com/news/amgen-buys-decode-genetics-for-415m/ |work=GEN - Genetic Engineering and Biotechnology News |date=10 December 2012}}</ref>
*2013: In October, Amgen acquired [[Onyx Pharmaceuticals]], developer of Kyprolis ([[carfilzomib]]).<ref>{{cite news |last1=Wright |first1=Rob |title=Amgen's Acquisition Of Onyx Pharmaceuticals — Through The Eyes Of Tony Coles |url=https://www.lifescienceleader.com/doc/amgen-s-acquisition-of-onyx-pharmaceuticals-through-the-eyes-of-tony-coles-0001 |work=Life Science Leader |date=27 Aug 2018 |access-date=11 August 2022}}</ref>
*2015: In March, the company announced it would license its Phase II candidate drug [[AMG 714]] to developer [[Celimmune]] who plan to develop the anti-IL-15 [[monoclonal antibody]] for treatment against diet nonresponsive [[celiac disease]] and refractory celiac disease.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/celimmune-licenses-amgen-s-amg-714-for-celiac-disease/81250980/|title=GEN - News Highlights:Celimmune Licenses Amgen's AMG 714 for Celiac Disease|work=GEN}}</ref>
*2015: Repatha ([[evolocumab]]) was approved by the FDA in August.<ref>{{cite news |last1=Kolata |first1=Gina |title=F.D.A. Approves Repatha, a Second Drug for Cholesterol in a Potent New Class |url=https://www.nytimes.com/2015/08/28/health/fda-approves-another-in-a-new-class-of-cholesterol-drugs.html |work=The New York Times |date=27 August 2015 |access-date=11 August 2022}}</ref> In September the company announced it would acquire Dezima Pharma for more than $1.55 billion.<ref name="genengnews.com">{{cite web|url=http://www.genengnews.com/gen-news-highlights/for-up-to-1-55b-amgen-acquires-dezima-pharma/81251735/|title=For Up to $1.55B, Amgen Acquires Dezima Pharma|work=GEN|date=16 September 2015}}</ref><ref>{{Cite web |date=16 September 2015 |title=Amgen to buy Dezima Pharma for $300 million in cash |url=https://www.reuters.com/article/idUSKCN0RG1SL/ |access-date=22 November 2024 |website=Reuters}}</ref> The same day the company announced a collaboration with Xencor on 6 early stage immuno-oncology and inflammation programmes. As part of the deal Amgen will pay $45 million upfront, with the deal being worth up to another $1.7 billion.<ref>{{cite news|url=http://www.fiercebiotech.com/story/amgen-bets-17b-xencors-antibody-technology/2015-09-16|title=Amgen bets up to $1.7B on Xencor's antibody technology|work=FierceBiotech|date=16 September 2015 }}</ref><ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/amgen-xencor-to-partner-on-cancer-immunotherapy-inflammation-drugs/81251734/|title=Amgen, Xencor to Partner on Cancer Immunotherapy, Inflammation Drugs|work=GEN|date=16 September 2015}}</ref> In October, the FDA approved Imlygic.<ref>{{cite web |last1=Tontonoz |first1=Matthew |title=T-VEC is First FDA-Approved Oncolytic Virus Therapy |url=https://www.cancerresearch.org/en-us/blog/october-2015/fda-approves-first-in-new-class-of-immunotherapies |website=Cancer Research Institute |language=en |access-date=11 August 2022}}</ref>
*2016: In September, the company announced it would purchase the rights to [[Boehringer Ingelheim]]s Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of [[multiple myeloma]].<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/amgen-buys-rights-to-myeloma-bite-immunotherapy-from-boehringer-ingelheim/81253166/|title=Amgen Buys Rights to Myeloma BiTE Immunotherapy from Boehringer Ingelheim - GEN News Highlights - GEN|date=September 2016}}</ref> Also in September, the FDA approved Amjevita ([[adalimumab]]-atto).<ref name="Staton">{{cite news |last1=Staton |first1=Tracy |title=Amgen's Humira biosim, Amjevita, passes FDA milestone on long road to market |url=https://www.fiercepharma.com/pharma/amgen-s-humira-biosim-amjevita-passes-fda-milestone-long-road-to-market |work=Fierce Pharma |date=23 September 2016 |language=en |access-date=11 August 2022}}</ref>
*2017: The FDA approved Parsabiv in February<ref>{{cite news |last1=Bell |first1=Jacob |title=Amgen secures FDA approval for hormone drug |url=https://www.biopharmadive.com/news/amgen-fda-approval-parsabiv/435760/ |work=BioPharma Dive |access-date=11 August 2022 |date=8 February 2017}}</ref> and Mvasi ([[bevacizumab]]-awwb) in September.<ref name="Mvasi approval">{{cite web |title=FDA approves bevacizumab biosimilar Mvasi |url=https://www.gabionline.net/biosimilars/news/FDA-approves-bevacizumab-biosimilar-Mvasi |website=GaBI Online |language=en |date=22 September 2017 |access-date=11 August 2022}}</ref>
*2018:Amgen began constructing a next-generation [[biomanufacturing]] plant at its [[West Greenwich, Rhode Island]], campus in July.<ref>{{cite web |title=Amgen's New Bio-manufacturing Plant, Rhode Island, US |url=https://www.pharmaceutical-technology.com/projects/amgens-next-generation-bio-manufacturing-plant-rhode-island/ |website=Pharmaceutical Technology |date=10 August 2018 |access-date=11 August 2022}}</ref>
*2019: In January, Evenity ([[romosozumab]]) received approval in Japan,<ref>{{cite web |title=Evenity gets first ever approval, in Japan |url=https://www.thepharmaletter.com/article/evenity-gets-first-ever-approval-in-japan |website=The Pharma Letter |access-date=11 August 2022 |date=9 January 2019}}</ref><ref>{{cite news |last1=Taylor |first1=Phil |title=Amgen gets first OK for Evenity in Japan as FDA panel looms |url=https://www.fiercebiotech.com/biotech/amgen-gets-first-ok-for-evenity-japan-as-fda-panel-looms |access-date=11 August 2022 |work=Fierce Biotech |date=9 January 2019 |language=en}}</ref> followed by FDA approval in April.<ref>{{cite news |last1=Liu |first1=Angus |title=Amgen bone drug Evenity finally wins its FDA green light, but there's a catch |url=https://www.fiercepharma.com/pharma/amgen-s-bone-drug-evenity-approved-by-fda-expected-caveat |work=Fierce Pharma |date=10 April 2019 |language=en |access-date=11 August 2022}}</ref> In June, Kanjinti ([[trastuzumab]]-anns) was approved by the FDA.<ref name="Kanjinti approval">{{cite web |title=FDA Approves Amgen's Trastuzumab Biosimilar, Kanjinti |url=https://www.centerforbiosimilars.com/view/fda-approves-amgens-trastuzumab-biosimilar-kanjinti |website=The Center For Biosimilars |language=en |date=13 June 2019 |access-date=11 August 2022}}</ref> Amgen announced it would acquire Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to enhance its drug discovery capabilities.<ref>{{cite news|url=https://uk.reuters.com/article/us-nuevolution-m-a-amgen-idUKKCN1SS0OC|archive-url=https://web.archive.org/web/20190522135225/https://uk.reuters.com/article/us-nuevolution-m-a-amgen-idUKKCN1SS0OC|url-status=dead|archive-date=May 22, 2019|title=Amgen to buy Copenhagen-based Nuevolution for $167 million|newspaper=Reuters|date=22 May 2019|via=uk.reuters.com}}</ref> In August the company announced it would acquire the [[Otezla]] drug programme from [[Celgene]] for $13.4 billion, as part of Celgene and [[Bristol-Myers Squibb]]s merger deal.<ref>{{Cite web|url=https://www.biospace.com/article/releases/amgen-to-acquire-otezla-for-13-4-billion-in-cash-or-approximately-11-2-billion-net-of-anticipated-future-cash-tax-benefits/?s=79|title = Amgen to Acquire Otezla® for $13.4 Billion in Cash, or Approximately $11.2 Billion Net of Anticipated Future Cash Tax Benefits| date=26 August 2019 }}</ref><ref>{{Cite news|url=https://uk.reuters.com/article/us-bristol-myers-divestiture-amgen/celgene-to-sell-psoriasis-drug-otezla-for-13-4-billion-to-amgen-idUKKCN1VG102|archive-url=https://web.archive.org/web/20190826111601/https://uk.reuters.com/article/us-bristol-myers-divestiture-amgen/celgene-to-sell-psoriasis-drug-otezla-for-13-4-billion-to-amgen-idUKKCN1VG102|url-status=dead|archive-date=August 26, 2019|title = Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion|newspaper = Reuters|date = 26 August 2019}}</ref> In October, Amgen announced it would be acquiring a 20.5% stake in the [[Beijing]]-based BeiGene for $2.7 billion.<ref>{{Cite web|url=https://www.statnews.com/2019/10/31/amgen-acquires-stake-in-beigene-to-expand-cancer-drug-business-to-china/|title=Amgen acquires stake in BeiGene to grow cancer drug business to China|date=31 October 2019}}</ref> In November, Amgen awarded a $2 million grant to the [[CDC Foundation]] to launch the latter's EmPOWERED Health Program, promoting patient engagement in decision making for their cancer treatment.<ref>{{Cite web |date=2021-12-09 |title=CDC Foundation Active Programs October 1, 2020 – September 30, 2021 |url=https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |url-status=live |archive-url=https://web.archive.org/web/20220115161004/https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |archive-date=2022-01-15 |access-date=2022-08-06 |website=[[CDC Foundation]]}}</ref> In December, the FDA approved Avsola ([[infliximab]]-axxq).<ref>{{cite news |title=FDA approves Avsola, fourth Remicade biosimilar |url=https://www.healio.com/news/rheumatology/20191206/fda-approves-avsola-fourth-remicade-biosimilar |work=www.healio.com |date=6 Dec 2019 |language=en |access-date=11 August 2022}}</ref>
*2020: In April, Amgen established Amgen K.K. as the company's wholly-owned affiliate in Japan.<ref>{{cite news |title=BRIEF-Amgen Establishes Wholly-Owned Affiliate In Japan |url=https://www.reuters.com/article/brief-amgen-establishes-wholly-owned-aff/brief-amgen-establishes-wholly-owned-affiliate-in-japan-idUSFWN2BO1OX |work=Reuters |date=1 April 2020 |language=en |access-date=11 August 2022}}</ref><ref>{{cite news |last1=Liu |first1=Angus |title=Amgen wades deeper into Asia with full control of an Astellas Japanese JV |url=https://www.fiercepharma.com/pharma-asia/amgen-wades-deeper-into-asia-by-assuming-full-control-astellas-japanese-jv |access-date=11 August 2022 |work=Fierce Pharma |date=23 January 2020 |language=en}}</ref> Amgen announced in July that the [[United States Court of Appeals for the Federal Circuit]] had upheld the validity of two Amgen patents that described and claimed Enbrel and methods for making it. The appellate court affirmed an August 2019 decision by the [[United States District Court for the District of New Jersey]] and rejected [[Sandoz]]'s attempt to invalidate the patents on Enbrel.<ref>{{cite news |title=Amgen defeats Novartis appeal over arthritis drug Enbrel's patents |url=https://www.reuters.com/article/us-amgen-novartis-enbrel/amgen-defeats-novartis-appeal-over-arthritis-drug-enbrels-patents-idUSKBN2426EG |work=Reuters |date=1 July 2020 |language=en |access-date=11 August 2022}}</ref> Amgen joined the [[Dow Jones Industrial Average]] on August 24, 2020.<ref>{{cite news |last1=Stevens |first1=Pippa |title=Salesforce, Amgen and Honeywell added to Dow in major shake-up to the average |url=https://www.cnbc.com/2020/08/24/salesforce-amgen-and-honeywell-added-to-dow-in-major-shakeup-to-the-average.html |work=CNBC |date=24 August 2020 |language=en |access-date=11 August 2022}}</ref> In September, Amgen and [[Eli Lilly and Company]] announced a global manufacturing collaboration for [[COVID-19]] antibody therapies.<ref>{{cite news |last1=Blankenship |first1=Kyle |title=Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails |url=https://www.fiercepharma.com/manufacturing/eli-lilly-amgen-join-forces-to-scale-production-covid-19-antibody-cocktails |access-date=11 August 2022 |work=Fierce Pharma |date=17 September 2020 |language=en}}</ref> On December 10, Amgen announced that it joined OneTen, a coalition of large employers that aims to hire and advance one million black Americans over the next ten years.<ref>{{cite news |last1=Manfredi |first1=Lucas |title=CEOs are driving an initiative to hire, train 1M Black workers over next 10 years |url=https://www.foxbusiness.com/economy/oneten-aims-to-hire-1-million-black-workers-over-next-10-years |work=FOXBusiness |date=18 January 2021 |access-date=11 August 2022}}</ref> Later that month, the FDA approved Riabni ([[rituximab]]-arrx), a biosimilar to Rituxan.<ref name="Riabni approval">{{cite news |title=FDA Approves Riabni, Third Biosimilar to Rituxan |url=https://www.clinicaloncology.com/FDA-Watch/Article/12-20/FDA-Approves-Riabni-Third-Biosimilar-to-Rituxan/61514 |access-date=20 September 2022 |work=Clinical Oncology News |date=18 December 2020}}</ref>
*2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, [[bemarituzumab]], for $1.9 billion.<ref>{{Cite web |title=Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash | date=4 March 2021 |url=https://www.biospace.com/article/releases/amgen-to-acquire-five-prime-therapeutics-for-1-9-billion-in-cash/?s=79}}</ref><ref>{{Cite news |date=4 March 2021 |title=Amgen bets on $1.9-billion Five Prime deal to grow in Asia-Pacific oncology market |newspaper=Reuters |url=https://www.reuters.com/article/us-five-prime-m-a-amgen/amgen-adds-gastric-cancer-drug-candidate-in-1-9-billion-five-prime-therapeutics-deal-idUSKBN2AW1PT}}</ref><ref>{{Cite web |date=2021-03-19 |title=How Amgen Acquired Five Prime for $1.9 Billion, Beating Out a Dozen Others |url=https://www.biospace.com/how-amgen-acquired-five-prime-for-1-9-billion-beating-out-a-dozen-others |access-date=2024-12-06 |website=BioSpace |language=en-US}}</ref> In the same month, Amgen acquired Rodeo Therapeutics for $720 million.<ref>{{Cite web |title=In Second Acquisition this Month, Amgen Buys Rodeo for $721 Million | date=31 March 2021 |url=https://www.biospace.com/article/amgen-to-buy-rodeo-therapeutics-in-721-million-deal/?s=79}}</ref><ref>{{Cite web |date=2021-03-19 |title=How Amgen Acquired Five Prime for $1.9 Billion, Beating Out a Dozen Others |url=https://www.biospace.com/how-amgen-acquired-five-prime-for-1-9-billion-beating-out-a-dozen-others |access-date=2024-09-11 |website=BioSpace |language=en-US}}</ref> The FDA approved Amgen's [[Sotorasib|Lumakras]] in May for treatment of patients with KRAS-G12C-mutated non-small cell lung cancer.<ref name="Lumakras approval">{{cite news |author=ASCO Post Staff |date=June 25, 2021 |title=FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC |publisher=ASCO Post |url=https://ascopost.com/issues/june-25-2021/fda-approves-sotorasib-for-kras-g12c-mutated-nsclc/ |access-date=March 4, 2022}}</ref> In June, Amgen and [[Kyowa Kirin]] announced joint plans to develop and commercialize a treatment for [[atopic dermatitis]].<ref>{{cite news |last1=Idrus |first1=Amirah Al |date=1 June 2021 |title=Amgen reunites with longtime partner Kyowa Kirin in $400M dermatitis deal |language=en |work=Fierce Biotech |url=https://www.fiercebiotech.com/biotech/amgen-reunites-longtime-partner-kyowa-kirin-400m-dermatitis-deal |access-date=20 September 2022}}</ref> In July, Amgen acquired Teneobio for $900 million.<ref>{{Cite web |last=Priyan |first=Vishnu |date=2021-10-20 |title=Amgen concludes acquisition of biotech company Teneobio for $2.5bn |url=https://www.pharmaceutical-technology.com/news/amgen-teneobio-acquisition/ |access-date=2024-09-11 |website=Pharmaceutical Technology |language=en-US}}</ref> In October, Amgen and Neumora Therapeutics announced a research and development collaboration focused on novel precision therapies for certain brain diseases.<ref>{{cite news |last1=Taylor |first1=Nick Paul |date=7 October 2021 |title=Meet Neumora, Arch's $500M, Amgen-partnered play for the targeted future of neuroscience R&D |language=en |work=Fierce Biotech |url=https://www.fiercebiotech.com/biotech/meet-neumora-arch-s-500m-amgen-partnered-play-for-targeted-future-neuroscience-r-d |access-date=20 September 2022}}</ref><ref>{{cite news |date=7 October 2021 |title=Amgen to invest $100 million in SoftBank-backed Neumora |language=en |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/amgen-invest-100-million-softbank-backed-neumora-2021-10-07/ |access-date=20 September 2022}}</ref> Amgen began construction on a new biomanufacturing plant in [[New Albany, Ohio]], in November.<ref>{{cite news |date=8 November 2021 |title=Amgen breaks ground on new biomanufacturing facility in Ohio, US |work=NS Healthcare |url=https://www.ns-healthcare.com/news/amgen-new-biomanufacturing-facility-in-us/ |access-date=20 September 2022}}</ref> In December, the FDA approved Amgen and AstraZeneca's Tezspire ([[tezepelumab]]) for severe [[asthma]].<ref name="Dunleavy">{{cite news |last1=Dunleavy |first1=Kevin |date=20 December 2021 |title=Amgen, AstraZeneca score FDA nod for blockbuster hopeful asthma drug Tezspire |language=en |work=Fierce Pharma |url=https://www.fiercepharma.com/pharma/amgen-astrazeneca-win-nod-for-tezspire-severe-asthma-drug-has-blockbuster-potential-analyst |access-date=20 September 2022}}</ref> The FDA also approved Amgen's Otezla for adults with plaque [[psoriasis]] of any severity level.<ref>{{cite news |date=20 December 2021 |title=U.S. FDA approves expanded use of Amgen's psoriasis drug |language=en |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/fda-approves-expanded-use-amgens-psoriasis-drug-2021-12-20/ |access-date=20 September 2022}}</ref>
*2022: In January, Amgen announced a research collaboration with Generate Biomedicines across multiple modalities and several therapeutic areas for up to $1.9 billion.<ref>{{cite news |last1=Armstrong |first1=Annalee |date=6 January 2022 |title=Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs |language=en |work=Fierce Biotech |url=https://www.fiercebiotech.com/biotech/amgen-chooses-generate-for-1-9b-biobucks-deal-to-churn-out-up-to-10-multi-modality-drug |access-date=23 September 2022}}</ref><ref>{{cite news |last1=Philippidis |first1=Alex |date=6 January 2022 |title=Amgen, Generate Launch Up-to-$1.9B Protein Therapeutics Collaboration |work=GEN - Genetic Engineering and Biotechnology News |url=https://www.genengnews.com/topics/drug-discovery/therapeutics/protein-therapeutics/amgen-generate-launch-up-to-1-9b-protein-therapeutics-collaboration/ |access-date=23 September 2022}}</ref> The company also launched a multi-target collaboration with [[Arrakis Therapeutics]] to identify novel targeted RNA degrader therapeutics.<ref>{{cite news |last1=Armstrong |first1=Annalee |date=11 January 2022 |title=JPM 2022: Amgen teams up with Arrakis to destroy disease-causing RNA in $75M research deal |language=en |work=Fierce Biotech |url=https://www.fiercebiotech.com/biotech/amgen-teams-up-arrakis-to-destroy-disease-causing-rna-75m-research-deal |access-date=23 September 2022}}</ref><ref>{{cite news |last1=Pagliarulo |first1=Ned |date=11 January 2022 |title=Amgen partners with Arrakis to develop drugs aimed at RNA |work=BioPharma Dive |url=https://www.biopharmadive.com/news/amgen-arrakis-rna-degrader-small-molecule/616997/ |access-date=23 September 2022}}</ref> The next month, Amgen entered a multi-year collaboration with Plexium to discover novel targeted protein degradation therapies.<ref>{{cite news |last1=Shasteen |first1=Hayley |date=3 February 2022 |title=Amgen and Plexium Ink $500M Targeted Protein Degradation Therapies Pact |work=BioSpace |url=https://www.biospace.com/article/amgen-and-plexium-ink-500m-targeted-protein-degradation-therapies-pact/ |access-date=23 September 2022}}</ref><ref>{{cite news |last1=LaHucik |first1=Kyle |date=3 February 2022 |title=Amgen enters hot protein degradation field with $500M biobucks deal with Plexium |language=en |work=Fierce Biotech |url=https://www.fiercebiotech.com/biotech/amgen-lines-up-500m-biobucks-deal-plexium-for-protein-degradation-therapies |access-date=23 September 2022}}</ref> Also in February, Amgen issued its first [[green bond]] to fund various environmentally friendly initiatives across the company.<ref>{{cite news |last1=Pequeño IV |first1=Antonio |date=23 February 2022 |title=Amgen Issues 'Green Bond' |work=San Fernando Valley Business Journal |url=https://www.sfvbj.com/news/weekly-news/amgen-issues-green-bond/ |access-date=23 September 2022}}</ref><ref>{{cite news |last1=Mutua |first1=David Caleb |date=29 March 2022 |title=Amgen Mulls More Green Bonds After 'Robust Interest' in Debut |work=www.bloomberg.com |url=https://www.bloomberg.com/news/articles/2022-03-29/amgen-mulls-more-green-bonds-after-robust-interest-in-debut |access-date=23 September 2022}}</ref> The company broke ground on a new manufacturing facility in [[Holly Springs, North Carolina]], in March.<ref>{{cite web |last1=Parker |first1=Jason |title=Amgen expects new Holly Springs plant to be 'a permanent home' |url=https://wraltechwire.com/2022/03/07/amgen-expects-new-holly-springs-plant-to-be-a-permanent-home/ |website=WRAL TechWire |access-date=11 July 2023 |date=7 March 2022}}</ref><ref>{{cite news |last1=Sterling |first1=John |date=11 March 2022 |title=Amgen Breaks Ground on NC Biomanufacturing Facility |work=GEN - Genetic Engineering and Biotechnology News |url=https://www.genengnews.com/topics/bioprocessing/amgen-breaks-ground-on-nc-biomanufacturing-facility/ |access-date=23 September 2022}}</ref> In August, the company agreed to acquire ChemoCentryx for $3.7&nbsp;billion in an all-cash deal.<ref>{{Cite web |last=Priyan |first=Vishnu |date=2022-08-05 |title=Amgen to acquire biopharma firm ChemoCentryx for $3.7bn |url=https://www.pharmaceutical-technology.com/news/amgen-acquire-biopharma-chemocentryx/ |access-date=2024-09-11 |website=Pharmaceutical Technology |language=en-US}}</ref> ChemoCentryx is the maker of [[Tavneos]]—a drug treatment for rare diseases called anti-neutrophil cytoplasmic autoantibody-associated [[vasculitis]]—which was approved last year.<ref>{{cite news |url=https://www.wsj.com/articles/amgen-to-buy-chemocentryx-for-3-7-billion-11659614401 |title=Amgen to Buy ChemoCentryx for $3.7 Billion |date=4 August 2022 |work=[[The Wall Street Journal]] |last=Walker |first=Joseph |url-access=limited |archive-url=https://archive.today/20220804170316/https://www.wsj.com/amp/articles/amgen-to-buy-chemocentryx-for-3-7-billion-11659614401 |archive-date=4 August 2022 |url-status=live}}</ref> In December, the company announced it would acquire [[Horizon Therapeutics]] for $27.8 billion ($116.50 in cash for each Horizon share, a 20% premium) expanding its rare disease treatments.<ref>{{cite news | url=https://www.reuters.com/markets/deals/amgen-set-buy-biotech-firm-horizon-26-bln-valuation-bloomberg-news-2022-12-12/ | title=Amgen dives deeper into rare disease drugs with $27.8 BLN Horizon deal | newspaper=Reuters | date=12 December 2022 | last1=Mishra | first1=Manas | last2=Satija | first2=Bhanvi }}</ref> 
*2023: Amgen completed the acquisition of [[Horizon Therapeutics]] in October 2023.<ref>{{Cite news |url=https://www.reuters.com/markets/deals/amgen-completes-278-bln-horizon-deal-2023-10-06/ |title=Amgen completes $27.8 billion Horizon deal |date=6 October 2023 |work=Reuters}}</ref> In December, announced plans to use artificial intelligence in partnership with Amazon Web Services to help discover and create medicines.<ref name=":1">{{Cite web |date=2023-12-01 |title=Amgen forges ahead with generative AI to expedite advanced therapies |url=https://ventureburn.com/2023/12/amgen-forges-ahead-with-generative-ai-to-expedite-advanced-therapies/ |access-date=2023-12-07 |website=Ventureburn |language=en-ZA}}</ref> Amgen will use Amazon's SageMaker machine learning service to help with the  manufacturing process.<ref name=":1" />  That same month, it was confirmed that Amgen would sponsor the 2024 Irish Open as the title sponsor.<ref>{{Cite web |date=2023-12-14 |title=Irish Open sponsor name change after Amgen's takeover of Horizon |url=https://www.independent.ie/sport/golf/irish-open-sponsor-name-change-after-amgens-takeover-of-horizon/a2119441670.html |access-date=2024-12-06 |website=Irish Independent |language=en}}</ref>

== Amgen Foundation ==
In October 2017, the Amgen Foundation pledged $3 million to [[Khan Academy]] to support the development of free online biology lessons.<ref>{{cite news |last1=Vuocolo |first1=Alex |date=23 June 2020 |title=Khan Academy Founder Says $3M Grant Will Help Tackle Inequities in Virtual Education |url=https://cheddar.com/media/khan-academy-founder-says-m-grant-will-help-tackle-inequities-in-virtual-education |access-date=11 August 2022 |work=Cheddar News |language=en}}</ref><ref>{{cite news |last1=D'Angelo |first1=Alexa |date=29 October 2017 |title=Amgen Foundation awards Khan Academy $3 million to support development of biology |url=https://www.vcstar.com/story/news/education/2017/10/29/amgen-foundation-awards-khan-academy-3-million-support-development-biology/777379001/ |access-date=11 August 2022 |work=Ventura County Star}}</ref> In July 2020, Amgen granted an additional $3 million Khan Academy to support educational equity and science learning.<ref>{{cite news |date=24 July 2020 |title=Amgen Foundation awards $3 million to Khan Academy |url=https://philanthropynewsdigest.org/news/amgen-foundation-awards-3-million-to-khan-academy2 |access-date=20 September 2022 |work=Philanthropy News Digest}}</ref><ref>{{cite news |last1=Molina |first1=Brett |date=30 July 2020 |title=Q&A: Khan Academy CEO Sal Khan on the new school year and virtual learning |url=https://www.usatoday.com/story/tech/2020/07/30/khan-academy-ceo-sal-khan-prepping-fall-virtual-learning/5525480002/ |access-date=20 September 2022 |work=USA Today}}</ref>

In January 2020, the Amgen Foundation and [[Harvard University]] debuted LabXchange, a free online science education platform.<ref>{{cite news |last1=Kelly |first1=Rhea |date=24 January 2020 |title=Amgen and Harvard Launch Free Online Science Ed Platform -- Campus Technology |url=https://campustechnology.com/articles/2020/01/24/amgen-and-harvard-launch-free-online-science-ed-platform.aspx |access-date=11 August 2022 |work=Campus Technology |language=en}}</ref><ref>{{cite news |last1=Kahn |first1=Natalie L. |last2=Wang |first2=Andy Z. |date=8 April 2020 |title=Harvard's LabXChange Provides Platform for Remote Scientific Learning During Pandemic {{!}} News {{!}} The Harvard Crimson |url=https://www.thecrimson.com/article/2020/4/8/harvard-coronavirus-labxchange/ |access-date=11 August 2022 |work=The Harvard Crimson}}</ref> Amgen and the Amgen Foundation announced a commitment of up to $12.5 million to support COVID-19 relief efforts in March.<ref>{{cite news |date=25 March 2020 |title=Amgen, AT&T, Others Announce Commitments for COVID-19 Response |url=https://philanthropynewsdigest.org/news/amgen-at-t-others-announce-commitments-for-covid-19-response |access-date=20 September 2022 |work=Philanthropy News Digest}}</ref>

== Acquisitions ==
{{hidden start|toggle=left|title=The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):|titlestyle=background:white;}}
{{Tree list}}
*'''Amgen''' <small>(Founded 1983 as Applied Molecular Genetics)</small>
**Synergen Inc <small>(Acq 1994)</small><ref>{{cite news |last1=Olmos |first1=David |title=Amgen to Acquire Synergen in $239-Million Biotech Deal|url=https://www.latimes.com/archives/la-xpm-1994-11-19-fi-64446-story.html|access-date=4 November 2024 |work=Los Angeles Times |date=19 November 1994|language=en}}</ref>
**Kinetix Pharmaceuticals Inc <small>(Acq 2000)</small><ref>{{cite news |last1=Murphy |first1=Barbara |title=Amgen Agrees to Buy Drug Maker Kinetix|url=https://www.latimes.com/archives/la-xpm-2000-oct-24-me-41036-story.html|access-date=4 November 2024 |work=Los Angeles Times |date=24 October 2000|language=en}}</ref>
**Immunex Corporation <small>(Acq 2002)</small>
**Tularik Inc <small>(Acq 2004)</small>
**Abgenix Inc <small>(Acq 2006)</small>
**Avidia Inc <small>(Acq 2006)</small><ref>{{cite news |title=Amgen Agrees to Acquire Biotech Company Avidia
|url=https://www.wsj.com/articles/SB115953920781877969|access-date=27 January 2025 |work=The Wall Street Journal |date=29 September 2006|language=en}}</ref>
**Alantos Pharmaceuticals <small>(Acq 2007)</small><ref>{{cite news |title=Amgen to Acquire Alantos Pharmaceuticals|url=https://www.technologynetworks.com/drug-discovery/news/amgen-to-acquire-alantos-pharmaceuticals-186303|access-date=27 January 2025 |work=Technology Networks |date=8 June 2007|language=en}}</ref>
**Ilypsa Inc <small>(Acq 2007)</small><ref>{{cite news |title=Amgen to Acquire Ilypsa for $420M
|url=https://www.genengnews.com/news/amgen-to-acquire-ilypsa-for-420m/|access-date=27 January 2025 |work=GEN|date=5 June 2007|language=en}}</ref>
**BioVex Group Inc <small>(Acq 2011)</small>
**Micromet Inc <small>(Acq 2012)</small>
**Mustafa Nevzat İlaç <small>(Acq 2012)</small>
**KAI Pharmaceuticals <small>(Acq 2012)</small>
**[[deCODE genetics]] <small>(Acq 2012)</small>
**[[Onyx Pharmaceuticals]] <small>(Acq 2013)</small>
***[[Proteolix]]<small>(Acq 2009) </small>
**NextCODE genetics <small>(Spun off 2013)</small>
**Dezima Pharma <small>(Acq 2015)</small>
**Catherex <small>(Acq 2015)</small><ref>{{cite news|title=Medigene AG: Amgen acquires Medigene spin-off Catherex |url=https://www.fiercebiotech.com/biotech/medigene-ag-amgen-acquires-medigene-spin-off-catherex|access-date=23 October 2024 |work=Fierce Biotech|date=21 December 2015 |language=en}}</ref>
**Nuevolution AB <small>(Acq 2019)</small>
**Otezla ([[apremilast]]) <small>(Acq 2019)</small><ref>{{cite news |last1=Erman |first1=Michael |last2=Mishra |first2=Manas |title=Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion |url=https://www.reuters.com/article/us-bristol-myers-divestiture-amgen/amgen-to-buy-celgene-psoriasis-drug-otezla-for-13-4-billion-idUSKCN1VG102 |access-date=23 September 2022 |work=Reuters |date=26 August 2019 |language=en}}</ref>
**Five Prime Therapeutics <small>(Acq 2021)</small><ref>{{cite news |last1=Adams |first1=Ben |title=Prime time for Five Prime as Amgen snaps up this once-moribund biotech for $1.9B and its phoenix-from-the-flames cancer asset |url=https://www.fiercebiotech.com/biotech/amgen-pays-a-premium-for-five-prime-therapeutics-a-1-9b-cash-deal |access-date=23 September 2022 |work=Fierce Biotech |date=4 March 2021 |language=en}}</ref>
**Rodeo Therapeutics Corporation <small>(Acq 2021)</small><ref>{{cite news |last1=Idrus |first1=Amirah Al |title=Amgen saddles up with Rodeo for a $55M trek into regenerative medicine |url=https://www.fiercebiotech.com/biotech/amgen-drops-55m-upfront-for-rodeo-therapeutics-and-its-prostaglandin-blockers |access-date=23 September 2022 |work=Fierce Biotech |date=30 March 2021 |language=en}}</ref>
**Teneobio <small>(Acq 2021)</small>
**ChemoCentryx <small>(Acq 2022)</small><ref>{{cite news |last1=Philippidis |first1=Alex |title=Amgen to Acquire ChemoCentryx for $3.7B, Bolstering Autoimmune Portfolio |url=https://www.genengnews.com/topics/drug-discovery/therapeutics/autoimmune-disease-drugs/amgen-to-acquire-chemocentryx-for-3-7b-bolstering-autoimmune-portfolio/ |access-date=23 September 2022 |work=GEN - Genetic Engineering and Biotechnology News |date=5 August 2022}}</ref>
**[[Horizon Therapeutics]] <small>(Acq 2023)</small>
***Vidara Therapeutics International <small>(Acq 2014)</small>
***Hyperion Therapeutics <small>(Acq 2015)</small>
***Crealta Holdings  <small>(Acq 2015)</small>
***Raptor Pharmaceutical  <small>(Acq 2016)</small>
***River Vision Development Corp. <small>(Acq 2017)</small>
***Viela Bio Inc  <small>(Acq 2021)</small><ref>{{cite news |last1=Bell|first1=Jacob|last2=Fidler|first2=Ben |title=Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca|url=https://www.biopharmadive.com/news/horizon-acquires-astrazeneca-spinout-viela-bio/594265/ |access-date=20 December 2024 |work=Biopharma Dive |date=1 February 2021}}</ref>
{{Tree list/end}}
{{hidden end}}

== Products ==
Amgen's [[approved drug]]s or therapeutic biologicals include:

*Aimovig ([[erenumab-aooe]]) for [[migraine headaches]] (FDA approved May 2018)<ref>{{cite journal |last1=Raedler |first1=Lisa A. |date=15 April 2019 |title=Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults |url=https://www.ahdbonline.com/issues/2019/march-2019-vol-12-tenth-annual-payers-guide/2735-aimovig-erenumab-aooe-first-cgrp-receptor-antagonist-approved-for-the-prevention-of-migraine-in-adults |journal=American Health & Drug Benefits |language=en-gb |volume=12 |access-date=11 August 2022}}</ref>
*Amjevita ([[adalimumab]])<ref name="Staton"/> (FDA approved September 2016)
*Aranesp ([[darbepoetin alfa]]) for [[anemia]] (FDA approval in September 2001)<ref>{{cite news |last1=Pollack |first1=Andrew |date=19 September 2001 |title=F.D.A. Approves New Version of Amgen Drug |url=https://www.nytimes.com/2001/09/19/business/technology-fda-approves-new-version-of-amgen-drug.html |access-date=10 August 2022 |work=The New York Times}}</ref>
*Blincyto ([[blinatumomab]] for the treatment of [[acute lymphoblastic leukemia]])<ref>Food and Drug Administration December 3, 2014 [https://web.archive.org/web/20150128234353/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm425597.htm FDA Press release: Blinatumomab]</ref>
*Corlanor ([[ivabradine]])
*Enbrel ([[etanercept]]) for various forms of [[arthritis]]
*Epogen ([[erythropoietin]]) for [[anemia]]
*Evenity ([[romosozumab-aqqg]]) for [[osteoporosis]]
*Imlygic ([[talimogene laherparepvec]]) for local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma recurrent after initial surgery (FDA approved October 2015)<ref>{{Cite web |last=Berkrot |first=Bill |date=27 October 2015 |title=FDA approves Amgen's injected immunotherapy for melanoma |url=https://www.reuters.com/article/idUSKCN0SL2YG/ |access-date=6 December 2024 |website=Reuters}}</ref>
*Kanjinti ([[trastuzumab]]-anns)<ref name="Kanjinti approval"/> (FDA approved June 2019)
*Krystexxa ([[pegloticase]])
*Kyprolis ([[carfilzomib]])
*Lumakras ([[sotorasib]])<ref name="Lumakras approval"/>
*Mvasi ([[bevacizumab]]-awwb)<ref name="Mvasi approval"/>
*Neulasta ([[pegfilgrastim]]) for [[neutropenia]] (FDA approved 2002)<ref>{{cite news |date=2 Nov 2002 |title=FDA approves Amgen's new-generation filgrastim product, Neulasta |url=https://www.thepharmaletter.com/article/fda-approves-amgen-s-new-generation-filgrastim-product-neulasta |access-date=10 August 2022 |work=www.thepharmaletter.com}}</ref>
*Neupogen ([[granulocyte colony-stimulating factor]]) for [[neutropenia]]
*Nplate ([[romiplostim]]) for chronic [[immune thrombocytopenic purpura]] (FDA approved 2008)<ref>{{cite news |last1=Heavey |first1=Susan |date=22 August 2008 |title=U.S. FDA approves Amgen's blood platelet booster |url=https://www.reuters.com/article/us-amgen/u-s-fda-approves-amgens-blood-platelet-booster-idUSN2251359920080822 |access-date=10 August 2022 |work=Reuters |language=en}}</ref><ref>{{cite journal |last1=Jamali |first1=Faranak |last2=Lemery |first2=Steven |last3=Ayalew |first3=Kassa |last4=Robottom |first4=Suzanne |last5=Robie-Suh |first5=Kathy |last6=Rieves |first6=Dwaine |last7=Pazdur |first7=Richard |date=July 2009 |title=Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura |url=https://pubmed.ncbi.nlm.nih.gov/19711585/ |journal=Oncology (Williston Park, N.Y.) |volume=23 |issue=8 |pages=704–709 |issn=0890-9091 |pmid=19711585 |access-date=10 August 2022}}</ref>
*Otezla ([[apremilast]])<ref>{{cite news |last1=Jeffries |first1=Fleur |title=Amgen shares new Otezla data at American Academy of Dermatology congress 2022 |url=https://www.pmlive.com/pharma_news/amgen_shares_new_otezla_data_at_american_academy_of_dermatology_congress_2022_1389524 |access-date=11 August 2022 |work=PMLive |date=28 March 2022 |language=en}}</ref>
*Parsabiv ([[etelcalcetide]])
*Prolia ([[denosumab]]) for postmenopausal [[osteoporosis]]
*Repatha ([[evolocumab]])
*Riabni ([[rituximab]]-arrx)<ref name="Riabni approval"/>
*Sensipar/Mimpara ([[cinacalcet]] for primary and [[secondary hyperparathyroidism]], a mineral metabolism complication common in patients with kidney failure) (FDA approved 2004)<ref>{{cite web |date=1 May 2004 |title=New FDA Approvals |url=https://www.reliasmedia.com/articles/6766-new-fda-approvals |access-date=10 August 2022 |website=Relias Media}}</ref><ref>{{cite web |title=Drug Approval Package: Sensipar (Cinacalcet HCI) NDA #021688 |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688_Sensipar.cfm |archive-url=https://web.archive.org/web/20130218063129/http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688_Sensipar.cfm |url-status=dead |archive-date=February 18, 2013 |access-date=10 August 2022 |website=U.S. Food and Drug Administration}}</ref>
*Tepezza ([[teprotumumab]])
*Tezspire ([[tezepelumab]]-ekko)<ref name="Dunleavy"/>
*Tavneos ([[avacopan]])
*Uplizna ([[inebilizumab]])
*Vectibix ([[panitumumab]] for [[colon cancer]]) (FDA approved 2006)<ref>{{cite journal |last1=Giusti |first1=Ruthann M. |last2=Shastri |first2=Kaushikkumar A. |last3=Cohen |first3=Martin H. |last4=Keegan |first4=Patricia |last5=Pazdur |first5=Richard |date=May 2007 |title=FDA drug approval summary: panitumumab (Vectibix) |url=https://pubmed.ncbi.nlm.nih.gov/17522246/#:~:text=On%20September%2027%2C%202006%2C%20the,progression%20on%20or%20following%20fluoropyrimidine%2D%2C |journal=The Oncologist |volume=12 |issue=5 |pages=577–583 |doi=10.1634/theoncologist.12-5-577 |issn=1083-7159 |pmid=17522246 |s2cid=9376408 |access-date=10 August 2022}}</ref>
*Xgeva ([[denosumab]]) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone in adults with bone metastases from solid tumors)

===Products developed and then sold off===
* Kepivance ([[palifermin]] for [[oral mucositis]], sold to Biovitrium, now [[Swedish Orphan Biovitrum]], in December 2008<ref name=BiovitriumDeal>Amgen press office. [http://www.amgen.com/media/biovitrum_amgen_deal.html Biovitrum Closes Product Acquisition Deal with Amgen] {{webarchive |url=https://web.archive.org/web/20120703015728/http://www.amgen.com/media/biovitrum_amgen_deal.html |date=July 3, 2012 }}</ref>
*StemGen ([[ancestim]]) for use in combination with [[filgrastim]] for mobilizing peripheral [[hematopoietic stem cells]]<ref>{{cite web|url=http://www.sobi.com/en/Healthcare-Professionals/Products-alphabetical-list/Stemgen/|title=Stemgen® (ancestim)|work=sobi.com|access-date=2013-12-30|archive-url=https://web.archive.org/web/20131230232434/http://www.sobi.com/en/Healthcare-Professionals/Products-alphabetical-list/Stemgen/|archive-date=2013-12-30|url-status=dead}}</ref>) (sold to Biovitrium, now Swedish Orphan Biovitrum, in December 2008)<ref name=BiovitriumDeal/>
*Kineret ([[anakinra]]) for [[rheumatoid arthritis]], exclusively licensed to Biovitrium, now Swedish Orphan Biovitrum, in December 2008<ref name=BiovitriumDeal/>
In 2019, the company's largest selling products were Enbrel ([[etanercept]]),<ref>{{cite news |last1=Blankenship |first1=Kyle |date=27 July 2020 |title=The top 20 drugs by global sales in 2019 |url=https://www.fiercepharma.com/special-report/top-20-drugs-by-global-sales-2019 |access-date=12 July 2022 |work=Fierce Pharma |language=en}}</ref> a [[tumor necrosis factor]] blocker used in the treatment of [[rheumatoid arthritis]] and other autoimmune diseases, and Neulasta ([[pegfilgrastim]]), an [[immunostimulator]] used to prevent infections in patients undergoing cancer [[chemotherapy]].<ref>{{cite news |last1=Hagen |first1=Tony |date=4 February 2021 |title=Amgen Profits Get a Ride on Biosimilar Growth |url=https://www.centerforbiosimilars.com/view/amgen-profits-get-a-ride-on-biosimilar-growth |access-date=12 July 2022 |work=The Center For Biosimilars |language=en}}</ref>

==Pipeline and clinical trials==
As of August 2022, Amgen had 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I.<ref>{{cite web |title=Amgen Pipeline |url=https://www.amgenpipeline.com/ |website=Amgen Pipeline |language=en |access-date=16 August 2022}}</ref>

In September 2019, FDA granted [[fast track designation]] to [[sotorasib]] for the treatment of metastatic [[non-small-cell lung carcinoma]] (NSCLC) with the KRAS G12C mutation.<ref>{{cite news | url = https://www.targetedonc.com/news/fda-grants-amg-510-fast-track-designation-for-kras-g12c-nsclc | title = FDA Grants AMG 510 Fast Track Designation for KRAS G12C+ NSCLC | author = Lisa Astor | date = September 9, 2019 | publisher = targetedonc.com | access-date = November 16, 2019}}</ref>

In August 2020, Amgen, [[Takeda Pharmaceutical Company|Takeda]], and [[AbbVie]], as part of a COVID-19 research and development (R&D) alliance, announced the first patients enrolled in the I-SPY COVID clinical trial. The trial evaluated the efficacy of Otezla and two other medicines in severely ill, hospitalized COVID-19 patients who required high-flow oxygen.<ref>{{cite news |last1=Liu |first1=Angus |title=AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study |url=https://www.fiercepharma.com/pharma/abbvie-amgen-and-takeda-test-anti-inflammatory-drugs-joint-covid-19-study |work=Fierce Pharma |date=3 August 2020 |language=en}}</ref>

In October 2020, Amgen announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib in 126 patients with KRAS G12C-mutant advanced NSCLC who had failed three or fewer prior lines of anti-cancer therapies (including [[immunotherapy]] and/or chemotherapy).<ref>{{cite news |last1=Helwick |first1=Caroline |title=Phase II CodeBreak 100 Validates Early Benefit for KRAS Inhibitor in NSCLC |url=https://ascopost.com/news/february-2021/phase-ii-codebreak-100-validates-early-benefit-for-kras-inhibitor-in-nsclc/ |work=The ASCO Post |date=1 Feb 2021 |language=en |access-date=16 August 2022}}</ref> Amgen, the Global Coalition for Adaptive Research, and [[Eisai (company)|Eisai Co., Ltd.]] also announced enrollment of the first patient in a study testing multiple interventions for the treatment of patients hospitalized with COVID-19.<ref>{{cite news |title=Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More |url=https://finance.yahoo.com/news/biotech-stock-roundup-gilds-veklury-142402319.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAG67gWZ0Uz_ETxjRL4s4BXICGhSU-iHlDxHnjhSa0BR7Qk1Q24a7qn-W0TPvaYYWqbih0e-uSWs_Ua5cZ_H8M3rG5nZLUGz24LMMPuCaOgO_CCi3el4QhctetvixUNeq2-XJSLcTSl4JUPYmn1M5LIoiiW69CdkamEgvr0JH82kG |work=Yahoo Finance |date=28 Oct 2020 |access-date=16 August 2022}}</ref><ref>{{cite news |last1=Ross |first1=Casey |title=Drug companies deliver a vote of confidence in adaptive trial for Covid-19 |url=https://www.statnews.com/2020/11/10/adaptive-trials-covid19-amgen-eisai/ |access-date=16 August 2022 |work=STAT |date=10 November 2020}}</ref>

In November 2020, Amgen, Takeda, and [[UCB (company)|UCB]], as part of the COVID R&D alliance, announced the first patient enrolled in another trial evaluating Otezla and two other drugs as treatments for COVID-19.<ref>{{cite news |last1=Beasley |first1=Deena |title=COVID R&D Alliance launches trial of Amgen, UCB, Takeda drugs |url=https://www.reuters.com/article/us-health-coronavirus-treatment-trial/covid-rd-alliance-launches-trial-of-amgen-ucb-takeda-drugs-idUSKBN28A2Y7 |work=Reuters |date=30 November 2020 |language=en |access-date=16 August 2022}}</ref> Amgen also announced that it would terminate its collaboration with [[Cytokinetics]] and transition the development and commercialization rights for [[omecamtiv mecarbil]] and AMG 594.<ref>{{cite news |last1=Gardner |first1=Jonathan |title=Amgen cuts Cytokinetics loose after heart drug disappointment |url=https://www.biopharmadive.com/news/amgen-terminate-deal-cytokinetics-heart-failure-omecamtiv/589572/ |work=BioPharma Dive |date=23 Nov 2020 |access-date=16 August 2022}}</ref> Amgen and [[AstraZeneca]] announced positive topline results from a Phase 3 trial in which the investigational medicine [[tezepelumab]] demonstrated a statistically significant reduction in exacerbations in patients with severe asthma.<ref>{{cite news |last1=Dembeck |first1=Lauren |title=NAVIGATOR Trial Outcomes for Tezepelumab Use in Severe, Uncontrolled Asthma |url=https://www.pulmonologyadvisor.com/home/meetings/chest-2021/navigator-trial-outcomes-for-tezepelumab-use-in-severe-uncontrolled-asthma/ |work=Pulmonology Advisor |date=18 October 2021 |access-date=16 August 2022}}</ref>

In December 2020, the FDA granted [[breakthrough therapy]] designation to sotorasib for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation.<ref>{{cite news |last1=Taylor |first1=Nick Paul |title=Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib |url=https://www.fiercebiotech.com/biotech/amgen-plans-2020-filing-for-fda-approval-kras-drug-sotorasib |work=Fierce Biotech |date=8 December 2020 |language=en |access-date=16 August 2022}}</ref>

In May 2021, sotorasib received accelerated approval from FDA for treatment of adult patients with NSCLC whose tumors have a KRAS G12C mutation and who have received at least one prior systemic therapy; this was the first approved targeted therapy for tumors with any KRAS mutation.<ref>{{cite news | url = https://ascopost.com/issues/june-25-2021/fda-approves-sotorasib-for-kras-g12c-mutated-nsclc/ | title = FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC | author = ASCO Post Staff | date = June 25, 2021 | publisher = ascopost.com | access-date = March 4, 2022}}</ref> Similar approvals for sotorasib in NSCLC followed in January 2022 in Europe<ref>{{cite news | url = https://www.onclive.com/view/sotorasib-approved-in-europe-for-kras-g12c-mutated-advanced-nsclc | title = Sotorasib Approved in Europe for KRAS G12C–Mutated Advanced NSCLC | author = Kristi Rosa | date = January 10, 2022 | publisher = www.onclive.com | access-date = March 4, 2022}}</ref> and Japan.<ref>{{cite news | url = https://www.cancernetwork.com/view/sotorasib-earns-approval-in-japan-for-kras-g12c-nsclc | title = Sotorasib Earns Approval in Japan for KRAS G12C+ NSCLC | author = Audrey Sternberg | date = January 20, 2022 | publisher = cancernetwork.com | access-date = March 4, 2022}}</ref>

In September 2022, data from a late-stage study showed the company's cancer pill Lumakras beating out chemotherapy. This was the first approved drug in the set of treatments that target KRAS, among the most common generic mutations found in cancers but one where researchers have struggled for years to design drugs to treat. The drug was approved in 2021 with a list price of $17,900 per month.<ref>{{Cite news |last=Walker |first=Joseph |date=2022-09-12 |title=New Cancer Drug Beats Chemotherapy in Study |language=en-US |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/new-cancer-drug-beats-chemotherapy-in-study-11662996694 |access-date=2022-09-12 |issn=0099-9660}}</ref>

In March 2025, data for the drug Tezspire, showed the best results for treating chronic rhinosinusitis with nasal polyps.<ref>{{Cite web |last=Liu |first=Angus |date=2025-03-03 |title=Amgen, AZ Tezspire sinusitis data invite 'best-in-disease' talk |url=https://www.fiercepharma.com/pharma/amgen-astrazeneca-tezspire-sinusitis-data-spark-best-disease-talk-amid-sanofi-gsk |access-date=2025-03-05 |website=www.fiercepharma.com |language=en}}</ref> In the same month, Amgen announced the start of two late-stage trials for MariTide, a weight loss drug.<ref>{{Cite web |last=Garde |first=Damian |date=5 March 2025 |title=Amgen Starts Final-Stage Studies of Its Monthly Obesity Drug |url=https://www.bloomberg.com/news/articles/2025-03-05/amgen-starts-final-stage-studies-of-its-monthly-obesity-drug |access-date=5 March 2025 |website=Bloomberg}}</ref><ref>{{Cite web |last=Constantino |first=Annika Kim |date=2025-03-05 |title=Amgen starts two critical late-stage trials for weight loss drug MariTide |url=https://www.cnbc.com/2025/03/05/amgen-weight-loss-drug-maritide-starts-two-phase-three-trials.html |access-date=2025-03-05 |website=CNBC |language=en}}</ref>

==Carbon footprint==
Amgen reported Total [[carbon footprint|CO2e emissions]] (Direct + Indirect) for the twelve months ending 31 December 2020 at 243 Kt (-6 /-2.4% y-o-y)<ref name ="Amgen Total CO2e emissions">{{Cite web |title=Amgen's ESG Datasheet for 2020Q4 |url=https://www.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/responsibility-report/2020_summary_of_data.pdf?la=en&hash=9268352E8BA4A7FBE34F1F81ED7DC4E3}} [https://analytics.exerica.com/App/UnifiedId/0060E4B9B688755D0001EC99620100EA6971712E7A1304 Alt URL]</ref> and aims to reach net zero emissions by 2027.<ref>{{Cite web |title=Amgen's Sustainability Report for 2020Q4 |archive-url=https://web.archive.org/web/20210717063004/https://www.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/responsibility/amgen-2020-esg-report.pdf?la=en&hash=9BFE6598E279D7EA8553EE9A01CB76F0 |url=https://www.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/responsibility/amgen-2020-esg-report.pdf?la=en&hash=9BFE6598E279D7EA8553EE9A01CB76F0|archive-date=July 17, 2021 }} [https://analytics.exerica.com/App/Name/Amgen/Climate%20Goal&#91;Total%20CO2e%20emissions%20(Scope%201%20%2b%20Scope%202)&#93;/2020Q4/0/2020Q4 Alt URL]</ref>

{| class="wikitable"
|+ Amgen's annual Total CO2e Emissions - Location-Based Scope 1 + Scope 2 (in kilotonnes)<ref name="Amgen Total CO2e emissions"/>
|-
! Dec 2014 !! Dec 2015 !! Dec 2016 !! Dec 2017 !! Dec 2018 !! Dec 2019 !! Dec 2020
|-
| 354|| 369 || 292 || 279 || 264 || 249 || 243
|}

== Controversies ==
The ''[[Los Angeles Times]]'' reported on December 18, 2012, that Amgen pleaded guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 related [[whistleblower]] complaints. Federal prosecutors accused the company of pursuing profits while putting patients at risk.<ref>{{cite news |last=Terhune |first=Chad |date=18 December 2012 |title=Amgen pleads guilty to improper marketing of anemia drug Aranesp |url=https://www.latimes.com/business/la-xpm-2012-dec-18-la-fi-amgen-plea-20121219-story.html |access-date=2 February 2013 |work=Los Angeles Times}}</ref>  Larry Husten, a contributor at Forbes.com elaborates on AMGEN's illegal marketing practices in this case, namely that the "government accused Amgen of marketing Aranesp for indications not approved by the FDA and other illegal marketing practices".<ref>{{cite news |last=Husten |first=Larry |title=Amgen Pleads Guilty To Misbranding Anemia Drug Aranesp |url=https://www.forbes.com/sites/larryhusten/2012/12/18/amgen-pleads-guilty-to-misbranding-anemia-drug-aranesp/ |access-date=2 February 2013 |work=Forbes}}</ref>

== Public-private engagement ==
Amgen engages with the public and private sectors in a variety of settings including to promote [[research and development]], academic funding, event sponsorship, [[philanthropy]], and [[political lobbying]].

=== Academia ===

* [[Institute for Advanced Study]] - Donor to various IAS campaigns, including the IAS/Park City Mathematics Institute (PCMI), the Regional Initiative in Science and Education (RISE), and the Opportunity Equation (OE).<ref>{{Cite web |last1=Simonyi |first1=Charles |last2=Dijkgraaf |first2=Robbert |date=2013 |title=Report for the Academic Year 2012-2013 |url=https://www.ias.edu/sites/default/files/documents/publications/annualreport1213.pdf |url-status=live |archive-url=https://web.archive.org/web/20220802192438/https://www.ias.edu/sites/default/files/documents/publications/annualreport1213.pdf |archive-date=2022-08-02 |access-date=2022-08-02 |website=[[Institute for Advanced Study]]}}</ref>
* [[LA Promise Fund]] - Sponsor of the Amgen Biotech Experience Los Angeles (ABE-LA).<ref>{{Cite web |date=2022-02-23 |title=Amgen Biotech Experience (ABE-LA) |url=https://www.lapromisefund.org/programs/amgen-biotech-experience-abe-la/ |url-status=live |archive-url=https://web.archive.org/web/20220806050534/https://www.lapromisefund.org/programs/amgen-biotech-experience-abe-la/ |archive-date=2022-08-06 |access-date=2022-08-06 |website=[[LA Promise Fund]] |language=en-US}}</ref>
* [[University of Toronto]] - Donor to U of T's Boundless campaign.<ref>{{Cite web |title=Donor Listing |url=https://boundless.utoronto.ca/our-supporters/donor-listing/ |url-status=live |archive-url=https://archive.today/20210423095356/https://boundless.utoronto.ca/our-supporters/donor-listing/ |archive-date=2021-04-23 |access-date=2022-08-06 |website=[[University of Toronto]] |language=en }}</ref>
* [[University of Washington]] - Donor.<ref>{{Cite web |date=2020 |title=Honor Roll of Donors |url=https://uw-s3-cdn.s3.us-west-2.amazonaws.com/wp-content/uploads/sites/83/2020/10/29094302/RTC_HonorRoll_2020.pdf |url-status=live |archive-url=https://web.archive.org/web/20220610164520/https://uw-s3-cdn.s3.us-west-2.amazonaws.com/wp-content/uploads/sites/83/2020/10/29094302/RTC_HonorRoll_2020.pdf |archive-date=2022-06-10 |access-date=2022-08-05 |website=[[University of Washington]]; [[Amazon Web Services]]}}</ref>

=== Events and conferences ===

* Alberta Kidney Days - Virtual series sponsor.<ref>{{Cite web |last=BUKSA Strategic Conference Services |date=2021 |title=Virtual Series Sponsor Profile: Amgen |url=https://www.albertakidneydays.com/amgen |url-status=live |archive-url=https://web.archive.org/web/20220802200118/https://www.albertakidneydays.com/amgen |archive-date=2022-08-02 |access-date=2022-08-02 |website=Alberta Kidney Days Virtual Series |language=en-US}}</ref>
* BC Kidney Days - Sponsor.<ref>{{Cite web |date=2013 |title=Compassion in kidney care: from patients to providers |url=http://www.bcrenal.ca/resource-gallery/Documents/Final_program_design_web.pdf |url-status=live |archive-url=https://web.archive.org/web/20220108183210/http://www.bcrenal.ca/resource-gallery/Documents/Final_program_design_web.pdf |archive-date=2022-01-08 |access-date=2022-08-02 |website=[[BC Renal Agency]]}}</ref>
* Mentoring in IBD - Sponsor.<ref>{{Cite web |date=2022 |title=Sponsors |url=https://www.mentoringinibd.com/about-us/sponsors/ |url-status=live |archive-url=https://archive.today/20220419151936/https://www.mentoringinibd.com/about-us/sponsors/ |archive-date=2022-04-19 |access-date=2022-08-02 |website=Mentoring in IBD }}</ref>
* [[Princess Margaret Cancer Centre]] (PMCC) Conference - Sponsor.<ref>{{Cite web |date=2020-07-17 |title=The 8th Princess Margaret Hospital Conference: Developments in Cancer Management |url=https://fdocuments.in/document/years-of-success-anna-greenberg-richard-hill-michael-jewett-david-mccready-hans.html?page=6 |url-status=live |archive-url=https://web.archive.org/web/20220620072213/https://fdocuments.in/document/years-of-success-anna-greenberg-richard-hill-michael-jewett-david-mccready-hans.html?page=6 |archive-date=2022-06-20 |access-date=2022-08-05 |website=FDocuments India}}</ref>

=== Health care ===

* [[Kingston General Hospital]] - Donor.<ref>{{Cite web |date=2019-12-31 |title=Recognizing your contribution |url=http://kingston.akanewmedia.com/ |url-status=live |archive-url=https://web.archive.org/web/20220803225345/https://www.uhkf.ca/Your-Impact/Recognizing-Your-Contribution |archive-date=2022-08-03 |access-date=2022-08-04 |website=[[Kingston University Hospital Foundation]] |language=en-CA}}</ref>
* [[Princess Margaret Cancer Centre]] - Donor to the Princess Margaret Cancer Foundation.<ref>{{Cite web |last1=Fukakusa |first1=Janice |last2=Yamashita |first2=Miyo |title=2021 Annual Report |url=https://thepmcf.ca/getmedia/9b96649e-83ba-490a-bacc-f961904b94c8/Annual-Report-2021_Digital.pdf |url-status=live |archive-url=https://web.archive.org/web/20211120191604/https://thepmcf.ca/getmedia/9b96649e-83ba-490a-bacc-f961904b94c8/Annual-Report-2021_Digital.pdf |archive-date=2021-11-20 |access-date=2022-08-05 |website=[[Princess Margaret Cancer Centre]]}}</ref>
* [[Providence Health Care (Vancouver)|Providence Health Care]] - Donor.<ref>{{Cite web |title=Donor List |url=https://annualreport2019.providencehealthcare.org/donors/ |url-status=live |archive-url=https://archive.today/20220208021711/https://annualreport2019.providencehealthcare.org/donors/ |archive-date=2022-02-08 |access-date=2022-08-05 |website=[[Providence Health Care (Vancouver)|Providence Health Care]] |language=en-US}}</ref>
* [[Scarborough Health Network]] - Donor to the SHN Foundation.<ref>{{Cite web |date=2021 |title=Our Donors |url=https://www.shnfoundation.ca/our-donors/ |url-status=live |archive-url=https://web.archive.org/web/20220805175207/https://www.shnfoundation.ca/our-donors/ |archive-date=2022-08-05 |access-date=2022-08-05 |website=[[Scarborough Health Network|Scarborough Health Network Foundation]] |language=en-CA}}</ref>
* [[SickKids]] - Donor to the SickKids Foundation.<ref>{{Cite web |date=2021 |title=2020-21 SickKids Annual Report |url=https://web.sickkidsfoundation.com/annual-report-2020/ |url-status=live |archive-url=https://web.archive.org/web/20220620073404/https://web.sickkidsfoundation.com/annual-report-2020/ |archive-date=2022-06-20 |access-date=2022-08-05 |website=[[SickKids|SickKids Foundation]]}}</ref>
* [[Sinai Health System]] - Donor to the Sinai Health Foundation.<ref>{{Cite web |date=2021-03-31 |title=Donor List - Cumulative |url=https://www.sinaihealthannualreport.ca/donor-list-cumulative |url-status=live |archive-url=https://web.archive.org/web/20220806043705/https://www.sinaihealthannualreport.ca/donor-list-cumulative |archive-date=2022-08-06 |access-date=2022-08-06 |website=[[Sinai Health System|Sinai Health Annual Report]] |language=en}}</ref>
* [[St. Michael's Hospital (Toronto)|St. Michael's Hospital]] - Donor.<ref name=":0">{{Cite web |date=2021 |title=St. Michael's Foundation 2020/21 Annual Report |url=https://online.flippingbook.com/view/383454962/41/?sharedOn= |url-status=live |archive-url=https://web.archive.org/web/20220805044043/https://online.flippingbook.com/view/383454962/41/ |archive-date=2022-08-05 |access-date=2022-08-05 |website=FlippingBook}}</ref>
* [[Sunnybrook Health Sciences Centre]] - Donor to the Sunnybrook Foundation.<ref>{{Cite web |date=2022 |title=Our donors - Your Impact |url=https://sunnybrook.ca/foundation/your-impact/our-donors-2021.html |url-status=live |archive-url=https://web.archive.org/web/20220806044053/https://sunnybrook.ca/foundation/your-impact/our-donors-2021.html |archive-date=2022-08-06 |access-date=2022-08-06 |website=[[Sunnybrook Health Sciences Centre|Sunnybrook Foundation]] |language=en}}</ref>
* [[Unity Health Toronto]] - Donor.<ref name=":0"/>
* [[University Health Network]] - Donor to the UHN Foundation.<ref>{{Cite web |last1=Hanson |first1=Tennys |last2=Kothari |first2=Raj |title=2020/21 Report to Our Donors |url=https://uhnfoundation.ca/who-we-are/publications/2020-21-report-to-our-donors/ |url-status=live |archive-url=https://web.archive.org/web/20220507012703/https://uhnfoundation.ca/who-we-are/publications/2020-21-report-to-our-donors/ |archive-date=2022-05-07 |access-date=2022-08-06 |website=[[University Health Network|UHN Foundation]] |language=en-US}}</ref>
* [[Women's College Hospital]] - Donor.<ref>{{Cite web |title=Donor Listings |url=https://womenscollegehospitalfoundation.com/recognizing-our-donors/donor-listings/ |url-status=live |archive-url=https://web.archive.org/web/20220805043530/https://womenscollegehospitalfoundation.com/recognizing-our-donors/donor-listings/ |archive-date=2022-08-05 |access-date=2022-08-05 |website=Women's College Hospital Foundation |language=en-US}}</ref>

=== Media ===

* [[National Geographic Society]] - Donor.<ref>{{Cite web |title=The Power of Philanthropy |url=https://media.nationalgeographic.org/assets/file/2016_Annual_Report_DONOR_LIST_FINAL.pdf |url-status=live |archive-url=https://web.archive.org/web/20220510054615/https://media.nationalgeographic.org/assets/file/2016_Annual_Report_DONOR_LIST_FINAL.pdf |archive-date=2022-05-10 |access-date=2022-08-04 |website=[[National Geographic Society]]}}</ref>

=== Medical societies ===

* [[American Society of Hematology]] - Corporate funder.<ref>{{Cite web |date=2022 |title=Corporate Support |url=https://www.hematology.org/about/corporate-support |url-status=live |archive-url=https://archive.today/20220610180740/https://www.hematology.org/about/corporate-support |archive-date=2022-06-10 |access-date=2022-08-02 |website=[[American Society of Hematology]] |language=en }}</ref>
* [[Arthritis Society]] (Canada) - Partner.<ref>{{Cite web |date=2022 |title=Partners |url=https://arthritis.ca/about-us/partners |url-status=live |archive-url=https://archive.today/20220514211808/https://arthritis.ca/about-us/partners |archive-date=2022-05-14 |access-date=2022-08-02 |website=[[Arthritis Society]] }}</ref>
* [[Canadian Society of Hospital Pharmacists]] - Donor to the CSHP Foundation.<ref>{{Cite web |title=2019 Donors to the CSHP Foundation by Giving Level |url=https://cshp-scph.ca/foundation-2019-donors |url-status=live |archive-url=https://archive.today/20220419194211/https://cshp-scph.ca/foundation-2019-donors |archive-date=2022-04-19 |access-date=2022-08-04 |website=[[Canadian Society of Hospital Pharmacists]]}}</ref>
* [[Canadian Society of Nephrology]] - Corporate partner.<ref>{{Cite web |date=2022 |title=Our Partners |url=https://www.csnscn.ca/our-partners/ |url-status=live |archive-url=https://archive.today/20220108161403/https://www.csnscn.ca/our-partners/ |archive-date=2022-01-08 |access-date=2022-08-02 |website=CSN/SCN |language=en-US}}</ref>
* [[Endocrine Society]] - Corporate liaison board member.<ref>{{Cite web |date=2022 |title=Corporate Liaison Board |url=https://www.endocrine.org/membership/corporate-liaison-board |url-status=live |archive-url=https://archive.today/20220610234024/https://www.endocrine.org/membership/corporate-liaison-board |archive-date=2022-06-10 |access-date=2022-08-02 |website=[[Endocrine Society]] |language=en }}</ref>
* [[European Society of Cardiology]] - Sponsor for the EORP registry programme.<ref>{{Cite web |date=2022 |title=Why sponsor the EURObservational Registry Programme |url=https://www.escardio.org/Research/Registries-&-surveys/Sponsorship,%20https://www.escardio.org/Research/Registries-&-surveys/Sponsorship |url-status=live |archive-url=https://web.archive.org/web/20220615200902/https://www.escardio.org/Research/Registries-&-surveys/Sponsorship |archive-date=2022-06-15 |access-date=2022-08-03 |website=[[European Society of Cardiology]]}}</ref>
* [[Federation of Medical Women in Canada]] - Sponsor.<ref>{{Cite web |date=2010 |title=AGM 2010: The Many Faces of Medical Women |url=https://fmwc.ca/wp-content/uploads/2013/12/FMWC_Fall_Issue_2010.pdf |url-status=live |archive-url=https://web.archive.org/web/20220306100332/https://fmwc.ca/wp-content/uploads/2013/12/FMWC_Fall_Issue_2010.pdf |archive-date=2022-03-06 |access-date=2022-08-03 |website=[[Federation of Medical Women in Canada]]}}</ref>

=== Political lobbying ===

* [[Alliance for a Stronger FDA]] - Member.<ref>{{Cite web |date=2022-03-04 |title=List of Members |url=https://www.strengthenfda.org/members |url-status=live |archive-url=https://archive.today/20220708045902/https://www.strengthenfda.org/members |archive-date=2022-07-08 |access-date=2022-08-02 |website=Alliance for a Stronger FDA |language=en-US}}</ref>
* [[Alliance for Aging Research]] - Donor.<ref>{{Cite web |last= |first= |date=2022 |title=How We're Funded Advocacy & Support |url=https://www.agingresearch.org/about-us/how-were-funded/ |url-status=live |archive-url=https://web.archive.org/web/20220715161317/https://www.agingresearch.org/about-us/how-were-funded/ |archive-date=2022-07-15 |access-date=2022-08-02 |website=[[Alliance for Aging Research]] |language=en-US}}</ref>
* [[BIOTECanada]] - Member.<ref>{{Cite web |date=2021-12-23 |title=Member Listings |url=https://www.biotech.ca/about/member-listings/ |url-status=live |archive-url=https://web.archive.org/web/20220802194706/https://www.biotech.ca/about/member-listings/ |archive-date=2022-08-02 |access-date=2022-08-02 |website=[[BIOTECanada]] |language=en-US}}</ref>
* [[Bipartisan Policy Center]] - Donor.<ref>{{Cite web |last=Grumet |first=Jason |date=2016 |title=Dialogue Issue III: The Annual Report Issue 2015-2016 |url=https://bipartisanpolicy.org/download/?file=%2Fwp-content%2Fuploads%2F2019%2F08%2FAnnual-Report-2015.pdf |url-status=live |archive-url=https://web.archive.org/web/20220707072632/https://bipartisanpolicy.org/download/?file=%2Fwp-content%2Fuploads%2F2019%2F08%2FAnnual-Report-2015.pdf |archive-date=2022-07-07 |access-date=2022-08-02 |website=[[Bipartisan Policy Center]]}}</ref>
* [[The Business Council]] - Member, represented by Amgen chairman and CEO [[Robert A. Bradway]].<ref>{{Cite web |date=2022 |title=Active Members |url=https://businesscouncil.com/active-members/ |url-status=live |archive-url=https://archive.today/20220713065051/https://businesscouncil.com/active-members/ |archive-date=2022-07-13 |access-date=2022-07-02 |website=[[The Business Council]]}}</ref>
* [[CDC Foundation]] - Funding partner.<ref>{{Cite web |date=2021-12-09 |title=CDC Foundation Active Programs |url=https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |url-status=live |archive-url=https://web.archive.org/web/20220115161004/https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |archive-date=2022-01-15 |access-date=2022-08-02 |website=[[CDC Foundation]]}}</ref>
* [[Centre for Commercialization of Regenerative Medicine]] (CCRM) - Industry partner.<ref>{{Cite web |date=2019-04-10 |title=Industry Network |url=https://www.ccrm.ca/regenerative-medicine-cell-gene-therapy-industry-network/ |url-status=live |archive-url=https://web.archive.org/web/20220802203335/https://www.ccrm.ca/regenerative-medicine-cell-gene-therapy-industry-network/ |archive-date=2022-08-02 |access-date=2022-08-02 |website=CCRM |language=en-US}}</ref>
* [[Council on Foreign Relations]] - Affiliate.<ref>{{Cite web |title=Corporate Members |url=https://www.cfr.org/membership/corporate-members |access-date=2022-08-02 |website=Council on Foreign Relations |language=en}}</ref>
* [[European Federation of Pharmaceutical Industries and Associations]] (EFPIA) - Member.<ref>{{Cite web |date=2022 |title=Membership |url=https://www.efpia.eu/about-us/membership/ |url-status=live |archive-url=https://web.archive.org/web/20220701031757/https://www.efpia.eu/about-us/membership/ |archive-date=2022-07-01 |access-date=2022-08-02 |website=[[European Federation of Pharmaceutical Industries and Associations]]}}</ref>
* [[Foundation for the National Institutes of Health]] (FNIH) - Donor.<ref>{{Cite web |title=2020 Donors |url=https://2020-annual-report.fnih.org/donors/ |url-status=live |archive-url=https://web.archive.org/web/20220316135206/https://2020-annual-report.fnih.org/donors/ |archive-date=2022-03-16 |access-date=2022-08-03 |website=FNIH 2020 Annual Report |language=en}}</ref>
* [[Global Health Progress]] - Partner.<ref>{{Cite web |date=2022 |title=Explore Our Collaborations |url=https://globalhealthprogress.org/explore-our-collaborations/ |url-status=live |archive-url=https://web.archive.org/web/20220403013206/https://globalhealthprogress.org/explore-our-collaborations/ |archive-date=2022-04-03 |access-date=2022-08-04 |website=Global Health Progress |language=en-GB}}</ref> GHP is a multinational resource hub hosted by the [[International Federation of Pharmaceutical Manufacturers & Associations]] (IFPMA).
* [[Health Products Stewardship Association]] - Member.<ref>{{Cite web |last= |first= |date=2022 |title=Members |url=https://healthsteward.ca/members/hpsa-members/ |url-status=live |archive-url=https://archive.today/20220427100339/https://healthsteward.ca/members/hpsa-members/ |archive-date=2022-04-27 |access-date=2022-08-04 |website=Health Products Stewardship Association |language=en-US }}</ref>
* [[Innovative Medicines Canada]] - Member company.<ref>{{Cite web |date=2021 |title=Member Companies |url=http://innovativemedicines.ca/about/member-companies/ |url-status=dead |archive-url=https://web.archive.org/web/20220531235029/http://innovativemedicines.ca/about/member-companies/ |archive-date=2022-05-31 |access-date=2022-08-04 |website=[[Innovative Medicines Canada]]}}</ref>
* [[International Federation of Pharmaceutical Manufacturers & Associations]] (IFPMA) - Member.<ref>{{Cite web |title=Companies |url=https://www.ifpma.org/who-we-are/our-membership/full-members/companies/ |url-status=live |archive-url=https://web.archive.org/web/20220701150736/https://www.ifpma.org/who-we-are/our-membership/full-members/companies/#!/ |archive-date=2022-07-01 |access-date=2022-08-04 |website=IFPMA |language=en-GB}}</ref>
* [[Life Sciences British Columbia]] - Sponsor.<ref>{{Cite web |last= |date=2021-01-06 |title=Our Sponsors |url=https://lifesciencesbc.ca/membership/our-sponsors/ |url-status=live |archive-url=https://archive.today/20220425063149/https://lifesciencesbc.ca/membership/our-sponsors/ |archive-date=2022-04-25 |access-date=2022-08-04 |website=Life Sciences British Columbia |language=en-US }}</ref>
* [[Mayor of Los Angeles|Mayor's Fund for Los Angeles]] - Disaster relief grant provider.<ref>{{Cite web |last=Higgins |first=Connie |date=2020-04-28 |title=Amgen Foundation commits $2M to Ventura and Los Angeles Counties COVID-19 response |url=https://www.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/covid-19-info-center/amgen-thousand-oaks-amgen-foundation-grant-media_4-28-20.pdf |url-status=live |archive-url=https://web.archive.org/web/20220706190815/https://www.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/covid-19-info-center/amgen-thousand-oaks-amgen-foundation-grant-media_4-28-20.pdf |archive-date=2022-07-06 |access-date=2022-08-04 |website=Amgen}}</ref>
* [[National Health Council]] - Member.<ref>{{Cite web |last= |first= |date=2022 |title=Our Members |url=https://nationalhealthcouncil.org/members/ |url-status=live |archive-url=https://web.archive.org/web/20220406081753/https://nationalhealthcouncil.org/members/?m_cat=74&m_key= |archive-date=2022-04-06 |access-date=2022-08-05 |website=[[National Health Council]] |language=en-US}}</ref>
* [[Personalized Medicine Coalition]] - Member.<ref>{{Cite web |date=2021 |title=Current Members |url=https://personalizedmedicinecoalition.org/Members/Current_Members |url-status=live |archive-url=https://web.archive.org/web/20210815032705/https://personalizedmedicinecoalition.org/Members/Current_Members |archive-date=2021-08-15 |access-date=2022-08-05 |website=[[Personalized Medicine Coalition]] |language=en}}</ref>
* [[Pharmaceutical Advertising Advisory Board]] (PAAB) - Client.<ref>{{Cite web |last=Pharmaceutique |first=Pharmaceutical Advertising Advisory Board / Conseil Consultatif de Publicité |title=PAAB : About |url=https://www.paab.ca/about.htm |access-date=2022-08-05 |website=www.paab.ca |language=en}}</ref> PAAB "maintains a collaborative relationship” with [[Health Canada]].
* [[Pharmaceutical Research and Manufacturers of America]] (PhRMA) - Member.<ref>{{Cite web |title=About |url=https://phrma.org/About |url-status=live |archive-url=https://web.archive.org/web/20220805165515/https://www.phrma.org/about |archive-date=2022-08-05 |access-date=2022-08-05 |website=[[Pharmaceutical Research and Manufacturers of America]] |language=en}}</ref>
* [[Reagan-Udall Foundation|Reagan-Udall Foundation for the Food and Drug Administration]] - Donor.<ref>{{Cite web |last1=Winckler |first1=Susan C. |last2=Woodcock |first2=Janet |date=2021-07-01 |title=Annual Report 2020 |url=https://reaganudall.org/sites/default/files/2021-07/7-1-21_Reagan-Udall_AR.pdf |url-status=live |archive-url=https://web.archive.org/web/20220712065838/https://reaganudall.org/sites/default/files/2021-07/7-1-21_Reagan-Udall_AR.pdf |archive-date=2022-07-12 |access-date=2022-08-05 |website=[[Reagan-Udall Foundation]]}}</ref>
* [[Research!America]] - Member.<ref>{{Cite web |date=2022 |title=Member Organizations |url=https://www.researchamerica.org/about-us/member-organizations |url-status=dead |archive-url=https://archive.today/20220406092643/https://www.researchamerica.org/about-us/member-organizations |archive-date=2022-04-06 |access-date=2022-08-05 |website=[[Research!America]] }}</ref>

=== Professional associations ===

* [[British Columbia Pharmacy Association]] - Sponsor.<ref>{{Cite web |date=2022 |title=Our Sponsors and Prizes |url=https://www.bcpharmacy.ca/conference/prizes/2022 |url-status=live |archive-url=https://archive.today/20220523043337/https://www.bcpharmacy.ca/conference/prizes/2022 |archive-date=2022-05-23 |access-date=2022-08-02 |website=BC Pharmacy Association }}</ref>
* [[Canadian Association of Gastroenterology]] - Corporate sponsor.<ref>{{Cite web |date=2022 |title=Current Sponsors |url=https://www.cag-acg.org/partners/current-sponsors |url-status=live |archive-url=https://archive.today/20220421232040/https://www.cag-acg.org/partners/current-sponsors |archive-date=2022-04-21 |access-date=2022-08-02 |website=[[Canadian Association of Gastroenterology]]}}</ref>
* [[Canadian Association of Radiologists]] - Corporate partner.<ref>{{Cite web |date=2022 |title=Corporate Partners |url=https://car.ca/about/corporate-partners/ |url-status=live |archive-url=https://web.archive.org/web/20220719152812/https://car.ca/about/corporate-partners/ |archive-date=2022-07-19 |access-date=2022-08-02 |website=CAR - Canadian Association of Radiologists |language=en-US}}</ref>
* [[Canadian Rheumatology Association]] - Corporate sponsor.<ref>{{Cite web |date=2017-11-18 |title=Corporate Sponsors - CRA |url=https://rheum.ca/about-us/corporate-sponsors/ |url-status=live |archive-url=https://archive.today/20220301090853/https://rheum.ca/about-us/corporate-sponsors/ |archive-date=2022-03-01 |access-date=2022-08-02 |website=Canadian Rheumatology Association |language=en-US }}</ref>
* [[Canadian Urological Association]] - Corporate sponsor.<ref>{{Cite web |date=2021 |title=Home |url=https://cuameeting.org/en/ |url-status=live |archive-url=https://archive.today/20220516215917/https://cuameeting.org/en/ |archive-date=2022-05-16 |access-date=2022-08-02 |website=CUA Meeting 2022}}</ref>
* [[Colorectal Cancer Canada]] - Sponsor.<ref>{{Cite web |date=2021 |title=Our Partnerships |url=https://www.colorectalcancercanada.com/what-we-do/our-partnerships/ |url-status=live |archive-url=https://web.archive.org/web/20220516082302/https://www.colorectalcancercanada.com/what-we-do/our-partnerships/ |archive-date=2022-05-16 |access-date=2022-08-02 |website=Colorectal Cancer Canada |language=en}}</ref>
* [[Ontario Medical Association]] - Donor.<ref>{{Cite web |date=2022 |title=Your impact |url=https://www.oma.org/what-we-do/ontario-medical-foundation/your-impact/ |url-status=live |archive-url=https://web.archive.org/web/20220805021045/https://www.oma.org/what-we-do/ontario-medical-foundation/your-impact/ |archive-date=2022-08-05 |access-date=2022-08-05 |website=[[Ontario Medical Association]]}}</ref>

=== Research and development ===

* [[Alberta Kidney Disease Network]] - Grant provider.<ref>{{Cite journal |last1=Hemmelgarn |first1=Brenda R. |last2=Clement |first2=Fiona |last3=Manns |first3=Braden J. |last4=Klarenbach |first4=Scott |last5=James |first5=Matthew T. |last6=Ravani |first6=Pietro |last7=Pannu |first7=Neesh |last8=Ahmed |first8=Sofia B. |last9=MacRae |first9=Jennifer |last10=Scott-Douglas |first10=Nairne |last11=Jindal |first11=Kailash |date=2009-10-19 |title=Overview of the Alberta Kidney Disease Network |journal=BMC Nephrology |volume=10 |issue=1 |pages=30 |doi=10.1186/1471-2369-10-30 |issn=1471-2369 |pmc=2770500 |pmid=19840369 |doi-access=free }}</ref>
* [[Can-SOLVE CKD Network]] - Funding partner.<ref>{{Cite web |last= |date=2022 |title=Funding Partners |url=https://cansolveckd.ca/about/funding-partners/ |url-status=live |archive-url=https://web.archive.org/web/20220802200756/https://cansolveckd.ca/about/funding-partners/ |archive-date=2022-08-02 |access-date=2022-08-02 |website=Can-SOLVE CKD Network |language=en-CA}}</ref>
* [[Urban Institute]] - Donor.<ref>{{Cite web |last=Wartell |first=Sarah Rosen |title=2020 Annual Report |url=https://www.urban.org/sites/default/files/2021/11/01/2020-annual-report.pdf |url-status=live |archive-url=https://web.archive.org/web/20220630041643/https://www.urban.org/sites/default/files/2021/11/01/2020-annual-report.pdf |archive-date=2022-06-30 |access-date=2022-08-05 |website=[[Urban Institute]]}}</ref>

== Awards and recognition ==
Amgen was ranked 151 on the Fortune 500 list of the largest United States corporations by revenue in 2024.<ref>{{Cite web |title=Fortune 500 Full List (2024) |url=https://www.50pros.com/fortune500 |access-date=2024-11-12 |website=www.50pros.com}}</ref>

== See also ==
{{Portal|California|Companies}}
* ''[[Kirin-Amgen v Hoechst Marion Roussel]]'', a [[United Kingdom|UK]] [[patent]] case decided by the [[House of Lords]]
* ''[[Amgen Inc. v. Harris]]'', a United States Supreme Court case on employment law.
*[[Evolocumab]]
*''[[Amgen Inc v. Sanofi]]'', a United States Supreme Court case on patent enablement.

== References ==
{{Reflist|2}}

==External links==
{{Commons category}}
*{{Official website|http://www.amgen.com/}}
* {{OpenSecrets}}
{{Finance links
| name = Amgen
| symbol = AMGN
| sec_cik = 318154
| yahoo = AMGN
| google = AMGN:NASDAQ
}}
 
{{Pharmaceutical companies of the United States}}
{{Dow Jones Industrial Average companies}}
{{NASDAQ-100}}
{{Authority control}}

[[Category:Amgen| ]]
[[Category:Biotechnology companies of the United States]]
[[Category:Pharmaceutical companies]]
[[Category:Companies based in Thousand Oaks, California]]
[[Category:Companies listed on the Nasdaq]]
[[Category:Companies in the Dow Jones Industrial Average]]
[[Category:Companies in the Dow Jones Global Titans 50]]
[[Category:Life sciences industry]]
[[Category:Multinational companies headquartered in the United States]]
[[Category:Pharmaceutical companies established in 1980]]
[[Category:Biotechnology companies established in 1980]]
[[Category:Pharmaceutical companies of the United States]]
[[Category:1980 establishments in California]]
[[Category:1980s initial public offerings]]